<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medical therapies for Crohn disease in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medical therapies for Crohn disease in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Medical therapies for Crohn disease in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Naamah Zitomersky, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Athos Bousvaros, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melvin B Heyman, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1463461015"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Crohn disease (CD) is a chronic inflammatory condition that can affect any portion of the gastrointestinal tract from the mouth to the perianal area. Medical therapy is a cornerstone of management in all age groups. The choice of therapy varies depending upon the anatomic location and severity of the disease and treatment stage (induction versus maintenance of remission).</p><p>This review focuses on the characteristics of the medications used for CD in children. Other aspects of the diagnosis and management of children with CD are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5865.html" rel="external">"Clinical manifestations and complications of inflammatory bowel disease in children and adolescents"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5893.html" rel="external">"Growth failure and pubertal delay in children with inflammatory bowel disease"</a>.)</p><p></p><p class="headingAnchor" id="H3566743742"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>For CD affecting the ileum and/or colon, a variety of medications are available  (<a class="graphic graphic_table graphicRef65046" href="/d/graphic/65046.html" rel="external">table 1</a>). The choice of medication typically depends on disease location, severity, response, and benefits and risks of each therapy. These therapies can be grouped as <strong>induction therapies</strong>, which have relatively rapid onset of action, and <strong>maintenance therapies</strong>, which are appropriate for long-term use. Some treatments, such as anti-tumor necrosis factor (anti-TNF) therapies, are appropriate for both induction and maintenance.</p><p>The main options and general considerations are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoids</strong> – Systemic glucocorticoids (eg, <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>, <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a>) or <a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">budesonide</a> are appropriate for induction in moderate to severe CD [<a href="#rid1">1</a>]. In the United States, glucocorticoids are a common but declining initial treatment for the acute therapy. (See <a class="local">'Glucocorticoids'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exclusive or partial enteral nutrition</strong> – Exclusive enteral nutrition (EEN) is an appropriate approach for induction in patients with moderate to severe CD, especially for those with extensive small bowel involvement or growth failure. This approach is common in Canada and the United Kingdom and less widely used in the United States [<a href="#rid2">2,3</a>]. A form of partial enteral nutrition combined with a specific exclusion diet (known as the "CD exclusion diet") shows some promise for improving symptoms in children with mild to moderate CD. (See <a class="local">'Exclusive or partial enteral nutrition'</a> below and  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Nutritional therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infliximab</strong><strong> or </strong><strong>adalimumab</strong> – <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>, which are anti-TNF antibodies, are the main biologic agents used for CD in children. These drugs are used for initial medical treatment of high-risk patients with severe disease or for those with moderate disease due to patient preference and other patient-specific considerations (see <a class="local">'Anti-tumor necrosis factor antibody medications'</a> below). They are also common choices for maintenance therapy in patients with moderate or severe disease. (See <a class="local">'First-line biologic agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunomodulators</strong> – Immunomodulators used for CD are thiopurines (<a class="drug drug_pediatric" data-topicid="12582" href="/d/drug information/12582.html" rel="external">6-mercaptopurine</a> [6-MP] or <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> [AZA]) and <a class="drug drug_pediatric" data-topicid="12595" href="/d/drug information/12595.html" rel="external">methotrexate</a> (MTX). These are appropriate only for maintenance because of delayed onset of action. (See <a class="local">'Mercaptopurine and azathioprine'</a> below and <a class="local">'Methotrexate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminosalicylates</strong> – Aminosalicylates are sometimes utilized for induction and maintenance in mild CD; they have low toxicity but questionable efficacy. The choice of agent depends on disease location. (See <a class="local">'Aminosalicylates'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics</strong> – Antibiotics are important components of treatment for patients with abdominal abscess and are used in conjunction with percutaneous drainage. Oral antibiotics such as <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a>, <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a>, and <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> also have a limited role in the treatment of mild to moderate active CD, especially for patients with perianal disease but also for those with colonic disease. (See <a class="local">'Antibiotics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medications</strong> – A variety of therapies, including <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>, <a class="drug drug_pediatric" data-topicid="126474" href="/d/drug information/126474.html" rel="external">ustekinumab</a>, certolizumab, <a class="drug drug_pediatric" data-topicid="129934" href="/d/drug information/129934.html" rel="external">golimumab</a>, and <a class="drug drug_pediatric" data-topicid="13090" href="/d/drug information/13090.html" rel="external">thalidomide</a>, have been used for children with refractory CD. Because of limited pediatric data, these drugs are usually used as second-line therapy in patients who fail treatment with immunomodulators and anti-TNF antibodies. However, there are pediatric data that support the efficacy and safety of some of the newer biologic agents, including ustekinumab and vedolizumab. (See <a class="local">'Other medications'</a> below.)</p><p></p><p>The properties of these medications are discussed below. An approach to selecting among these medications is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef64031" href="/d/graphic/64031.html" rel="external">algorithm 1</a>) and discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Selection of medical treatment'</a>.)</p><p class="headingAnchor" id="H136762961"><span class="h1">INDUCTION THERAPY</span></p><p class="headingAnchor" id="H1599516875"><span class="h2">Glucocorticoids</span><span class="headingEndMark"> — </span>In the United States, glucocorticoids remain a common initial medical treatment for the acute therapy of moderate to severe CD. Glucocorticoids are considered short-term induction therapies. Patients who respond to induction with glucocorticoids should transition to a long-term maintenance treatment (usually an immunomodulator or biologic).</p><p>Glucocorticoids are not appropriate for maintenance therapy, because they are associated with important long-term side effects, including growth failure, osteopenia, hirsutism, diabetes, psychosis, cataracts, and altered body shape and image. Moreover, they are not effective for maintaining remission [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H3432921315"><span class="h3">Methylprednisolone</span><span class="headingEndMark"> — </span>For patients with severe disease at presentation, an intravenous glucocorticoid (eg, <a class="drug drug_pediatric" data-topicid="12601" href="/d/drug information/12601.html" rel="external">methylprednisolone</a>) is given initially because it provides the most rapid glucocorticoid effect. This drug is typically given as 1 mg/kg per dose every 12 hours, up to a maximum of 30 mg every 12 hours, then transitioned to oral glucocorticoids if the patient demonstrates a good clinical response. Some clinicians use higher doses (eg, 2 mg/kg every 12 hours, maximum 40 mg per dose).</p><p class="headingAnchor" id="H2970150465"><span class="h3">Prednisone</span><span class="headingEndMark"> — </span>In patients with moderate disease and active mucosal inflammation, <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> or <a class="drug drug_pediatric" data-topicid="12723" href="/d/drug information/12723.html" rel="external">prednisolone</a> given orally usually brings rapid improvement in most patients. Starting doses are 1 to 2 mg/kg/day (maximum 60 mg daily). Once remission is achieved, glucocorticoids can be tapered.</p><p>Although glucocorticoids are effective for inducing remission in most patients, many become glucocorticoid dependent or require surgery. This was illustrated in a retrospective study that described the natural history of CD from 1970 to 1993, a period when glucocorticoids were the most effective available medical therapy for CD [<a href="#rid5">5</a>]. Although 80 percent of patients were in remission after 30 days, after 12 months, 28 percent were still glucocorticoid dependent and 38 percent had undergone surgery.</p><p class="headingAnchor" id="H3408785022"><span class="h3">Budesonide</span><span class="headingEndMark"> — </span>Enteric-coated <a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">budesonide</a> (eg, Entocort), designed for release in the ileum and cecum, is an alternative to oral <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a>. Budesonide is probably less effective than prednisone, but also has fewer side effects, because of high first-pass hepatic metabolism. It is only effective for disease in the ileum and ascending colon (right colon) (see  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease"</a>). A newer formulation, budesonide MMX, is a once-daily oral formulation of budesonide that is designed to release budesonide throughout the colon using Multi-Matrix System (MMX) technology. This formulation has been studied in mild to moderate ulcerative colitis [<a href="#rid6">6</a>]. Budesonide MMX has not been studied in children with CD. However, based on its efficacy in ulcerative colitis, it is a potential option in children with CD limited to the colon and may help to reduce toxicity from systemic steroids.</p><p>The initial starting dose of the ileal-release form of <a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">budesonide</a> for an adolescent or adult is 9 mg/day, tapered by 3 mg increments. There are few data on the optimal dosing in children. The adult dose of 9 mg/day has been used in clinical trials in children six years and older [<a href="#rid7">7,8</a>]. A retrospective study of 62 children used oral budesonide in doses of 0.45 mg/kg/day (maximum dose 9 mg/day) for the treatment of mild to moderate CD [<a href="#rid9">9</a>]. Budesonide MMX comes only in 9 mg preparations, so tapering of this agent involves going to 9 mg every other day for two weeks, then 9 mg every three days for two weeks, then discontinuing it.</p><p>Studies in adults and small pediatric studies suggest that <a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">budesonide</a> is slightly less effective than <a class="drug drug_pediatric" data-topicid="12725" href="/d/drug information/12725.html" rel="external">prednisone</a> in inducing remission in active disease but is associated with fewer side effects (moon facies, acne, adrenal suppression) [<a href="#rid7">7</a>]. One pediatric study showed that the response rate to budesonide for induction is approximately 48 percent, compared with 77 percent for prednisone, and that prednisone is effective rescue therapy in approximately 75 percent of patients who do not respond to budesonide [<a href="#rid9">9,10</a>].</p><p><a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">Budesonide</a> should not be used as long-term maintenance therapy of CD. Although it offers the advantage of less systemic toxicity compared with other glucocorticoids, patients treated long-term with budesonide still may experience growth failure, either because of direct suppression of linear growth or an inability to fully control disease activity [<a href="#rid11">11</a>]. Moreover, placebo-controlled trials in adults showed that it was not effective for maintenance therapy [<a href="#rid12">12</a>].</p><p>Topical <a class="drug drug_pediatric" data-topicid="13096" href="/d/drug information/13096.html" rel="external">budesonide</a> (liquid or foam enema) may be used for patients with left-sided colonic disease. (See  <a class="medical medical_review" href="/d/html/4061.html" rel="external">"Overview of budesonide therapy for adults with inflammatory bowel disease", section on 'Rectal formulations'</a>.)</p><p class="headingAnchor" id="H1686399454"><span class="h2">Exclusive or partial enteral nutrition</span><span class="headingEndMark"> — </span>Exclusive enteral nutrition (EEN; also known as primary nutritional therapy) can be used as an alternative or supplement to glucocorticoids or other antiinflammatory medications. It is a good option for motivated children and families who wish to avoid glucocorticoids and other medications (at least in the short term). It promotes mucosal healing in a patient with active disease and suppresses intestinal inflammation, possibly by altering the gut microflora [<a href="#rid13">13-15</a>].</p><p>EEN consists of providing all nutritional needs through a liquid formula. If a course of EEN is successful, the patient is typically transitioned to one of the maintenance medications described below. Additional courses of EEN can be used for re-induction after a relapse. Because long courses of EEN are a major burden to the patient, EEN is rarely used as a maintenance therapy, although periodic use of EEN (eg, four weeks every four months) may help promote weight gain and maintain remission [<a href="#rid16">16</a>]. Details about the technique, efficacy, and patient selection are discussed separately.</p><p>An alternative approach is to combine partial enteral nutrition with a specific whole foods-based exclusion diet, known as the CD exclusion diet. This form of nutritional therapy is more easily accepted by patients than EEN and appears to be at least as effective in inducing remission [<a href="#rid17">17</a>]. This approach is undergoing further study but is increasingly utilized in clinical practice. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Nutritional therapy'</a>.)</p><p class="headingAnchor" id="H2221391375"><span class="h2">Anti-tumor necrosis factor antibody medications</span><span class="headingEndMark"> — </span>In certain high-risk patients, treatment with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> early in the disease course may be beneficial compared with other induction therapies  (<a class="graphic graphic_algorithm graphicRef75566" href="/d/graphic/75566.html" rel="external">algorithm 2</a>). We usually use this strategy for patients with extensive small bowel disease, severe ulcerating colonic disease, growth failure in mid- to late puberty, severe perianal disease, or steroid-unresponsive disease because these patients have an increased risk of poor disease outcome. The decision is also guided by the preferences of the patient and family or caregivers. For patients without these risk factors, it is unclear whether this approach is beneficial compared with other induction therapies. The limited evidence about potential benefits and risks for early use of these drugs is discussed separately. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'High-risk patients'</a>.)</p><p>Details about the use of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> and <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>, including dosing, efficacy, safety, and decisions about use in combination with other immunosuppressive medications, are discussed below. (See <a class="local">'Infliximab'</a> below and <a class="local">'Adalimumab'</a> below and <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> below.)</p><p class="headingAnchor" id="H2756307630"><span class="h2">Aminosalicylates</span><span class="headingEndMark"> — </span>5-aminosalicylates (5-ASA) are sometimes used for induction in patients with mild disease (eg, mild colitis, limited ileal disease). If the patient responds, the drug is continued for maintenance of remission. However, no formal trials have assessed the efficacy of these agents for induction in pediatric CD. The use of aminosalicylates for CD is controversial, with some meta-analyses suggesting lack of efficacy, while others suggest moderate effectiveness in colonic disease [<a href="#rid18">18</a>]. Nevertheless, many clinicians do a trial of 5-ASA for patients with mild CD because they have low toxicity. If a patient does not enter clinical, laboratory, or endoscopic remission after six months of use, other alternatives are strongly encouraged. (See <a class="local">'Aminosalicylates'</a> below.)</p><p class="headingAnchor" id="H460930578"><span class="h1">MAINTENANCE MEDICATIONS</span></p><p class="headingAnchor" id="H2661868614"><span class="h2">First-line biologic agents</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> and <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> are monoclonal antibodies directed against tumor necrosis factor (TNF). These drugs are important options for patients with moderate or severe CD and have become the mainstay of induction and maintenance treatment for CD in North America and Europe  (<a class="graphic graphic_algorithm graphicRef75566" href="/d/graphic/75566.html" rel="external">algorithm 2</a>). They are also appropriate as initial therapy for patients with moderate or severe disease, especially those with features suggesting a high risk of complications (see <a class="local">'Anti-tumor necrosis factor antibody medications'</a> above). Other anti-TNF agents that are less often used for pediatric patients are discussed below. (See <a class="local">'Second-line biologic agents'</a> below.)</p><p class="headingAnchor" id="H3255069463"><span class="h3">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> is a chimeric monoclonal antibody directed against the cytokine TNF-alpha. It is approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe CD in children who have had an inadequate response to conventional therapy [<a href="#rid19">19</a>]. It is also increasingly used as first-line maintenance therapy and as induction therapy for patients with moderate to severe CD, especially those at high risk for complications [<a href="#rid3">3</a>]. (See <a class="local">'Anti-tumor necrosis factor antibody medications'</a> above.)</p><p>The pharmacology, efficacy, and safety of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> are discussed in detail separately. Data particularly relevant to its use in children are discussed here. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a>.)</p><p class="headingAnchor" id="H555663600"><span class="h4">Dose and administration</span><span class="headingEndMark"> — </span>The typical regimen for <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> consists of three initial "loading" doses of 5 mg/kg each at zero, two, and six weeks, with follow-up infusions at eight-week intervals if the patient responds. Regularly scheduled treatment rather than episodic use is important to optimize efficacy and avoid loss of response.</p><p>Patients who do not respond to the 5 mg/kg dose sometimes respond to dose intensification by either increasing the <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> dose (maximal dose usually up to 10 mg/kg every four weeks) or increasing the frequency of infusions (decreasing the interval to every four to six weeks) [<a href="#rid20">20-22</a>]. Indeed, a large case series from a tertiary care center found that 40 percent of children initially treated with 5 mg/kg required dose intensification [<a href="#rid23">23</a>]. Other studies also suggest that doses of 5 mg/kg every eight weeks are insufficient to achieve optimal infliximab levels in 40 to 60 percent of children, especially in children &lt;11 years or more severe disease [<a href="#rid24">24-27</a>]. (See <a class="local">'Monitoring infliximab levels and antibodies'</a> below.)</p><p>Patients with very early-onset inflammatory bowel disease (VEO-IBD) may require accelerated induction with high-dose <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>, guided by therapeutic drug monitoring, or alternative treatment options for certain types of VEO-IBD [<a href="#rid28">28-31</a>]. (See  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children", section on 'Very early-onset inflammatory bowel disease'</a>.)</p><p>Increasing evidence suggests that prompt dose intensification reduces the risk of developing anti-infliximab antibodies, reduces the risk of loss of response to therapy, and often achieves a sustained clinical response [<a href="#rid32">32,33</a>]. (See <a class="local">'Medical necessity of off-label use of medications in pediatrics'</a> below.)</p><p>A good response is suggested by improvement in clinical symptoms (eg, abdominal pain, fatigue, diarrhea, rectal bleeding) within four to eight weeks  (<a class="graphic graphic_table graphicRef100489" href="/d/graphic/100489.html" rel="external">table 2</a>). The response should ideally be confirmed within three to six months by objective data, such as improvements in erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), repeat imaging with magnetic resonance enterography (MRE), or colonoscopy. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Assessment of disease activity'</a>.)</p><p class="headingAnchor" id="H4053482118"><span class="h4">Monitoring infliximab levels and antibodies</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> trough levels and anti-infliximab antibodies are increasingly being utilized to monitor patients receiving infliximab therapy and to optimize dosing for each patient [<a href="#rid34">34</a>], although the optimal way to monitor patients has not yet been determined and the monitoring is costly [<a href="#rid35">35,36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infliximab</strong><strong> concentrations</strong> – The typical target for <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> trough concentration is &gt;5 micrograms/mL before the week 14 infusion. Several studies suggest that concentrations above this threshold are associated with a higher likelihood of remission in adults and children [<a href="#rid20">20,26,37-39</a>] and other studies support the use of higher thresholds and/or earlier monitoring [<a href="#rid40">40,41</a>]. Indeed, combination therapy (utilizing infliximab together with either <a class="drug drug_pediatric" data-topicid="12595" href="/d/drug information/12595.html" rel="external">methotrexate</a> [MTX] or a thiopurine) may work in part because the immunomodulator may raise infliximab levels [<a href="#rid42">42</a>]. (See <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> below.)</p><p></p><p class="bulletIndent1">Some experts have advocated for routine monitoring of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> trough levels at week 14 (the fourth infusion), permitting dose escalation before the development of clinical or laboratory disease activity [<a href="#rid20">20</a>]. In a prospective study in adult and pediatric patients, low anti-TNF drug concentrations at week 14 were associated with lower odds of remission at week 54 [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1">Experience with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> monitoring in adults with CD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Therapeutic drug monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-</strong><strong>infliximab</strong><strong> antibodies</strong> – In patients with low trough <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> concentration (eg, &lt;5 micrograms/mL) and active disease, the interpretation depends on the presence of anti-infliximab antibodies  (<a class="graphic graphic_table graphicRef117391" href="/d/graphic/117391.html" rel="external">table 3</a>), which develop in at least 25 percent of patients [<a href="#rid43">43</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with low or no levels of anti-infliximab antibodies (eg, &lt;10 U/mL) are likely to benefit from dose escalation [<a href="#rid44">44</a>]. In some cases, this may be due to increased stool losses of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> due to colonic inflammation, which is often correlated with low serum albumin concentrations or increased disease burden (ie, with more TNF to inhibit) [<a href="#rid24">24,34,45</a>]. A majority of these patients respond to dose optimization, and many of these revert to antibody-negative, as suggested by observational studies in children [<a href="#rid43">43</a>] and adults [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with high titers of anti-infliximab antibodies (eg, &gt;10 U/mL) and who are not responding to treatment are less likely to respond to dose escalation of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> because infliximab clearance is increased in patients with high anti-infliximab antibody titers [<a href="#rid21">21</a>]. However, it may be worth attempting dose escalation for these patients because a minority will respond [<a href="#rid43">43,46</a>]. Those who do not respond to dose escalation will need a different agent.</p><p></p><p class="headingAnchor" id="H2770736666"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> is generally more effective than AZA, 6-MP, or other immunomodulators in treating moderate to severe CD. It is typically used to treat patients whose disease is resistant to steroids [<a href="#rid47">47</a>] and also can help heal perianal fistulas refractory to therapy with antibiotics and AZA/6-MP [<a href="#rid48">48-50</a>]. It is also increasingly used early in the course of disease to treat patients with high risks for complicated CD, as discussed above. (See <a class="local">'Anti-tumor necrosis factor antibody medications'</a> above and  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a>.)</p><p>Initial studies in children suggest efficacy comparable with that achieved in adults [<a href="#rid51">51-55</a>]. Approximately 80 percent of children or adults have a response to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> [<a href="#rid56">56,57</a>]. Among those children who respond to infliximab, approximately 50 percent will remain in remission after one year. Approximately 20 percent of patients require dose intensification to maintain remission, which is accomplished by an increase in drug dose or an increase in infusion frequency [<a href="#rid58">58</a>]. An additional subset of patients experience loss of response despite dose intensification, which is in part mediated by the development of antibodies to infliximab. In one case series, loss of response was experienced by 10 percent of responders over a five-year period (2 to 6 percent per year), despite optimization of the regimen [<a href="#rid57">57</a>]. Concurrent treatment with immunomodulators (6-MP or AZA) modestly improves the response rate to infliximab [<a href="#rid59">59-61</a>]. Overall, approximately one-third of patients discontinue infliximab within two to three years, either because of primary nonresponse (2 to 13 percent), loss of response despite dose intensification (8 to 30 percent), or adverse events (5 to 8 percent) [<a href="#rid57">57,58,62-65</a>]. Many of these patients change to another agent (eg, <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>). (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a> and <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> below.)</p><p>In a multicenter open-label trial of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> in combination with an immunomodulator in 112 pediatric patients, 88 percent of subjects responded to 10 weeks of treatment with infliximab and 59 percent achieved clinical remission [<a href="#rid56">56</a>]. Among the responders, there were superior sustained remission rates in children receiving infusions every eight weeks compared with infusions every 12 weeks (56 versus 24 percent of patients were still in remission at 56 weeks). In a subpopulation of 23 patients with perianal disease, the perianal symptoms resolved in 70 percent and remained in remission through 54 weeks of maintenance therapy [<a href="#rid66">66</a>]. Seven percent of the subjects developed serious infections (pneumonia or Crohn-associated abscess, sepsis, or enterocolitis) [<a href="#rid56">56</a>]. Eighteen percent had an infusion reaction, but these usually did not require discontinuation of infliximab therapy. With long-term maintenance therapy, 80 percent had little or no disease activity for up to three years [<a href="#rid62">62</a>]. Limited data suggest that very young patients may not respond as well to infliximab therapy. In an observational study of 33 children younger than seven years of age with IBD (20 with CD, four with ulcerative colitis, and nine with indeterminate colitis), remission rates were 36 percent at one year, 18 percent at two years, and 12 percent at three years [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H1432246237"><span class="h4">Adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> is generally well tolerated, but as experience with the drug increases, concerns have been raised about the possibility of some rare but serious adverse effects. (See  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infusion reactions</strong> – The most common adverse effect of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> is an infusion reaction, which occurs in 15 to 35 percent of patients (approximately 5 percent of infusions) [<a href="#rid55">55,68-70</a>]. Infusion reactions can present with acute symptoms (chest tightness, shortness of breath, rash, vomiting, and/or blood pressure instability) or delayed symptoms (fever, arthritis, and rash occurring 2 to 14 days after an infusion). Some infusion reactions are caused by antibodies to infliximab. One study suggested that the probability of developing antibodies is reduced if patients are premedicated with intravenous <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> [<a href="#rid71">71</a>]. Other strategies for reducing antibody formation include the use of scheduled infusions rather than "on-demand" infusions and concomitant treatment with thiopurines or MTX [<a href="#rid71">71-73</a>].</p><p></p><p class="bulletIndent1">Many infusion reactions are mild and can be managed by intravenous glucocorticoids, <a class="drug drug_pediatric" data-topicid="13236" href="/d/drug information/13236.html" rel="external">diphenhydramine</a>, and a decrease in infusion rate. In a patient with a history of infusion reactions, subsequent infusions are typically managed by giving glucocorticoids orally for three to five days and/or an intravenous dose of <a class="drug drug_pediatric" data-topicid="13361" href="/d/drug information/13361.html" rel="external">hydrocortisone</a> immediately prior to the infusion. Test doses of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> (usually 0.1 mg over 15 minutes, followed by 1 mg) are given and, if tolerated, the treatment infusion is performed. Alternatively, a patient with a history of a reaction can be converted from infliximab to <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> (a humanized anti-TNF antibody that is effective in adult patients who are intolerant of infliximab).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serious infections</strong> – Like other biologic agents or immunomodulators, treatment with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> increases a patient's susceptibility to bacterial, fungal, and viral infections [<a href="#rid74">74-78</a>]. Before initiating treatment with any of these agents, we suggest that all patients undergo immunodiagnostic screening for tuberculosis, as well as baseline evaluation for vaccine-preventable infections, including measurement of titers for measles and hepatitis B virus (HBV) serologies and documentation of immunity to varicella  (<a class="graphic graphic_table graphicRef108934" href="/d/graphic/108934.html" rel="external">table 4</a>) [<a href="#rid75">75</a>]. Tests for latent tuberculosis are unreliable once the patient is on an anti-TNF agent or other strong immunosuppressant [<a href="#rid78">78</a>]. Special considerations for immunizations are discussed in a separate topic review. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Infection risk'</a> and  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Immunizations'</a>.)</p><p></p><p class="bulletIndent1">Serious infections reported in patients during treatment with these agents include bacterial sepsis, tuberculosis, nontuberculous mycobacterial infection, <em>Listeria</em> and disseminated varicella or cytomegalovirus infection, and <em>Legionella</em> <em>pneumophila</em> [<a href="#rid75">75,77,79,80</a>]. Advice for patients to help avoid infections is summarized in the table  (<a class="graphic graphic_table graphicRef108936" href="/d/graphic/108936.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a>.)</p><p></p><p class="bulletIndent1">The risk for invasive fungal infection has raised particular concern [<a href="#rid77">77,81</a>]. In 2008, the FDA issued a warning about the risk for pulmonary and disseminated histoplasmosis, coccidiomycosis, blastomycosis, aspergillosis, and other invasive fungal infections in patients undergoing treatment with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or other anti-TNF antibodies [<a href="#rid82">82</a>]. The warning is based on case reports of patients in whom histoplasmosis infection was not promptly recognized, and some of these patients died. Typical signs and symptoms of histoplasmosis and other invasive fungal infections include fever, malaise, weight loss, sweats, cough, dyspnea, pulmonary infiltrates on radiographs, or serious systemic illness including shock. Infection is acquired through inhalation of contaminated soil (eg, in chicken coops) in an endemic area, which includes parts of the midwestern United States (eg, the Ohio and Mississippi river valleys), Mexico, Central and South America, Africa, and Asia [<a href="#rid75">75</a>]. (See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections", section on 'Fungal infections'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – Most available data suggest a mildly increased risk of lymphoma and hepatosplenic T cell lymphoma (HSTCL) in patients receiving immunosuppressive therapy for CD, although the absolute risk remains low. The risk from monotherapy with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or other anti-TNF antibodies appears to be very small and probably less than for thiopurine monotherapy, although causality cannot be definitively determined, because the disease is extremely rare. In patients on combination therapy, the majority of the risk appears to be attributable to the thiopurine component [<a href="#rid83">83</a>] (see <a class="local">'Safety and monitoring'</a> below). However, lymphoma may also occur in patients receiving infliximab monotherapy [<a href="#rid84">84</a>]. Very limited data suggest that anti-TNF antibodies may increase the risk for melanoma. (See  <a class="medical medical_review" href="/d/html/7975.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Risk of malignancy"</a>.)</p><p></p><p class="bulletIndent1">Citing concerns about possible increased risks for lymphoma and other malignancies, the FDA performed a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-communication-update-tumor-necrosis-factor-tnf-blockers-and-risk-pediatric&amp;token=eEaZP6NLZgpW3FaDqUhBxq8WRf8Nq5tWMgfA%2F9fDM6J%2BUL2P3bgLROLOvVTtEnKGX%2F9qLGYwA7FF3xZUfAlgVSwGmEp7XK%2BY%2BzHN%2BT2Vs%2B%2By0gEddRKVMq8uc%2Bp%2BdLz9WmHXEA88dSqwX5qcwYuDaQ%3D%3D&amp;TOPIC_ID=120380" target="_blank">Safety Review of TNF inhibitors</a> and strengthened the warnings in the prescribing information. The FDA specifically recommended that discussions with patients and families include the risks and potential benefits of anti-TNF antibodies, as well as the risks and benefits of alternative treatments [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1">The malignancy concerns are central to decisions about use of immunomodulators in combination with an anti-TNF antibody. (See <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other serious complications with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> therapy have been reported, including miliary tuberculosis, other opportunistic infections [<a href="#rid86">86</a>], immune-mediated hepatitis [<a href="#rid87">87</a>], liver failure, autoimmune disease, demyelinating disease or other neurologic disorders [<a href="#rid88">88</a>], and one pediatric case of a fatal fulminant central nervous system process of unclear etiology [<a href="#rid89">89</a>]. Infliximab or other TNF inhibitors may also induce psoriasis in approximately 10 percent of patients, with average latency of approximately 1 year after starting the medication [<a href="#rid90">90-94</a>]. They probably also contribute to skin cancer risk in individuals with IBD [<a href="#rid95">95,96</a>]. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Skin monitoring and care'</a>.)</p><p></p><p class="headingAnchor" id="H1210613940"><span class="h4">Infliximab biosimilars</span><span class="headingEndMark"> — </span>Almost all studies of <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> in pediatric patients utilized the originator (aka "reference") product of infliximab. However, other pharmaceutical companies subsequently developed anti-TNF molecules with a similar chemical structure to infliximab, called infliximab biosimilars. Clinical trials in adults have demonstrated comparable efficacy and safety of infliximab biosimilars in patients with rheumatoid arthritis as well as IBD. However, pediatric data remain limited, though the few published studies again suggest comparable efficacy and safety [<a href="#rid97">97</a>]. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) suggested that "a switch from the originator infliximab (to a biosimilar) may be considered in children with IBD in clinical remission, following at least 3 induction infusions" [<a href="#rid98">98</a>]. However, ESPGHAN also recommends against multiple medication switches, as might be attempted in a patient with loss of efficacy, because it may be difficult to determine whether a specific product results in worse outcomes of disease. They also recommend keeping careful records of medications so that a hospital can ascertain whether a patient is receiving a reference product or biosimilar. Increasingly, switches from originator to biosimilar are being mandated by insurance due to cost savings [<a href="#rid99">99,100</a>]. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Biosimilars'</a>.)</p><p class="headingAnchor" id="H3620864045"><span class="h3">Adalimumab</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">Adalimumab</a> is an antibody directed against TNF and is approved by the FDA for the treatment of moderate to severe CD in children. Adalimumab is a humanized antibody, whereas <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> is a chimeric antibody. The development of a new citrate-free formulation has resulted in reduced patient discomfort during injection, which was one of the main impediments to use. Either infliximab or adalimumab may be used as "first-line" anti-TNF therapy in children.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Most experts consider <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> to be a reasonable first-line alternative to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> when anti-TNF antibody medication is indicated, for either induction (see <a class="local">'Anti-tumor necrosis factor antibody medications'</a> above) or maintenance therapy [<a href="#rid3">3</a>]. Adalimumab is also used as a second-line treatment for patients who lose response to or are intolerant of infliximab.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">Adalimumab</a> is administered by subcutaneous injection every two weeks. For adults and children ≥40 kg body weight, the manufacturer's label recommends a loading dose of 160 mg, followed by 80 mg two weeks later, and 40 mg every two weeks for maintenance. For children 17 to 40 kg body weight, the loading dose is 80 mg, followed by 40 mg two weeks later, and 20 mg every two weeks for maintenance. Escalation to weekly dosing is often necessary, guided by therapeutic drug monitoring and/or the clinical response. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">Adalimumab</a> appears to have similar efficacy to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>, based on indirect evidence from separate trials and clinical experience, but the drugs have not been directly compared in randomized trials. Advantages of infliximab include more extensive experience and less frequent dosing in the maintenance phase (every eight weeks in contrast with every two weeks). Advantages of adalimumab are reduced cost (because no infusion center is needed) and the convenience of administering the medication at home or school. In the past, injections of adalimumab were quite painful due to the low pH of the medium, but a newer citrate-free formulation has a higher pH and is far less painful.</p><p></p><p class="bulletIndent1">Most efficacy studies of <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> have been as a second-line therapy in patients who failed <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> therapy due to lack of response, infusion reaction, or development of anti-infliximab antibodies [<a href="#rid101">101-105</a>]. In one such study that included 115 children and adolescents treated with adalimumab, 70 percent had a clinical response at one year [<a href="#rid106">106</a>]. Most of these subjects had failed a prior trial of infliximab because of loss of response, infusion reaction, or intolerance. The IMAgINE 1 trial evaluated two maintenance dosing regimens of adalimumab in 188 pediatric patients with moderate to severe CD [<a href="#rid107">107</a>]. Subjects were enrolled only if they had failed treatment with oral glucocorticoids or an immunomodulator (thiopurine or MTX) and had responded to an open-label induction with adalimumab. Approximately 40 percent of patients had been previously treated with infliximab but had become unresponsive or had adverse reactions to that drug. The trial focused on the maintenance phase of adalimumab. A standard-dose group received 40 mg for body weight ≥40 kg or 20 mg for body weight &lt;40 kg, and a low-dose group received 20 mg for body weight ≥40 kg or 10 mg for body weight &lt;40 kg. After 26 weeks of maintenance therapy, during which these doses of adalimumab were given every two weeks, 33.5 percent of patients remained in clinical remission and there was no significant difference between the two dosing regimens. Most importantly, the patients who were infliximab-naïve had comparable remission rates to the REACH trial [<a href="#rid56">56</a>] (approximately 50 percent), while those who had previously been treated with infliximab and lost response had significantly lower remission rates (approximately 20 percent).</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">Adalimumab</a> is also efficacious as a first-line therapy for children with moderate to severe CD who have not been previously treated with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or other biologic agents. In a trial in this population, sustained corticosteroid-free remission was achieved in 80 percent of children managed with proactive monitoring and dose adjustment and in 48 percent of those managed with reactive dose adjustment [<a href="#rid108">108</a>]. Adalimumab also significantly improved linear growth and weight gain [<a href="#rid109">109,110</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects of <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> are similar to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> (see <a class="local">'Adverse effects'</a> above and  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>). Some patients have injection site reactions such as swelling or itching, which can be treated with premedication with an antihistamine.</p><p></p><p class="headingAnchor" id="H703610515"><span class="h2">Anti-TNF monotherapy versus combination therapy with an immunomodulator</span><span class="headingEndMark"> — </span>Decisions about use of combination therapy (anti-tumor necrosis factor [anti-TNF] antibody with an immunomodulator) are complex because of uncertainties about the relative risks and benefits of combination versus monotherapy. As a result, there is considerable variation in clinical practice among IBD specialists. Practice ranges from avoiding combination therapy altogether, to using combination therapy for a limited period of time, to continuing combination therapy indefinitely, and/or substituting MTX rather than thiopurines for the combination therapy [<a href="#rid3">3</a>]. Given the equipoise regarding the use of combination therapy, patient and family values and preferences are important when deciding between combination therapy or biologic monotherapy. A plain-language summary to guide this discussion is outlined in the table  (<a class="graphic graphic_table graphicRef107130" href="/d/graphic/107130.html" rel="external">table 6</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> (anti-TNF antibody with an immunomodulator) – Important considerations are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Potential risks</strong> – The main concern about combination therapy is that it might increase the risk of lymphoma as compared with monotherapy. Since large studies of IBD patients suggest that thiopurines confer a slight increase in lymphoma risk, it is logical to infer that thiopurine discontinuation might reduce that risk [<a href="#rid83">83,111,112</a>]. However, because the overall risk of lymphoma in this population is small, any increased risk conferred by combination therapy is probably also very small, albeit poorly defined. There is insufficient information to determine whether MTX in combination with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or other biologic agent is associated with lymphoma risk in IBD patients [<a href="#rid113">113,114</a>]. (See <a class="local">'Safety and monitoring'</a> below.)</p><p></p><p class="bulletIndent2">Another concern is that combination therapy might increase the risk of opportunistic infection compared with monotherapy [<a href="#rid83">83</a>]. Although use of multiple immunosuppressive medications generally increases risks for infections, this is balanced by a reduction in infection risk achieved by improving disease remission rates and minimizing steroid use, based primarily on studies in adults [<a href="#rid83">83,115</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Potential benefits</strong> – Combination therapy reduces the rate of antibody formation (which can cause loss of response to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>) [<a href="#rid116">116</a>]. It also improves remission rates as compared with monotherapy, based on evidence from large studies in adults with moderate or severe CD [<a href="#rid47">47</a>]. Similarly, in a study in children, patients treated with combination therapy for at least six months postinduction were substantially more likely to remain in remission compared with those treated with infliximab monotherapy (78 versus 54 percent at one year and 68 versus 46 percent at two years, respectively) [<a href="#rid117">117</a>]. Combination therapy is most likely to be beneficial for patients with risk factors for debilitating CD, such as those with fistulizing disease, perianal involvement, growth failure, or corticoid dependence [<a href="#rid83">83</a>]. The optimal duration and type of combination therapy remains uncertain [<a href="#rid118">118,119</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Implementation</strong> – For a patient who is not responding to immunomodulators (thiopurines, MTX), one approach is to add <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> to the immunomodulator and leave a patient on combination therapy for 6 to 12 months [<a href="#rid118">118</a>]. Then, if the patient is in remission, the patient may either continue on combination therapy or change to monotherapy with infliximab alone. This decision should be made collaboratively with the patient and family, after a detailed discussion about the risks and benefits of combination therapy versus monotherapy, acknowledging the limited information available  (<a class="graphic graphic_table graphicRef107130" href="/d/graphic/107130.html" rel="external">table 6</a>).</p><p></p><p class="bulletIndent2">After the immunomodulator is stopped, the disease relapses in some patients (approximately 10 percent in one case series [<a href="#rid120">120</a>]). In such cases, we suggest restarting combination therapy. For such patients, we usually use low-dose oral MTX with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>. However, if high titers of antibodies to infliximab are present, we generally switch to <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> or another biologic agent. We try to avoid long-term use of thiopurine with infliximab due to the rare risk of lymphoma.</p><p></p><p class="bulletIndent2">If combination therapy with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> is planned, use of MTX rather than a thiopurine has the potential benefit of providing a protective effect against antibody formation, while reducing lymphoma risk. In particular, we prefer MTX rather than thiopurines in young males because young males seem to be at increased risk for HSTCL. However, the benefits of using MTX as an adjunct to anti-TNF therapy have not been established, since the only study that demonstrates that MTX reduces antibodies to infliximab utilized higher-dose subcutaneous MTX [<a href="#rid121">121</a>]. Additional data are required to see if low-dose oral MTX is effective. (See <a class="local">'Methotrexate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-TNF monotherapy</strong> – Monotherapy with an anti-TNF antibody is a reasonable alternative to combination therapy. For this strategy, the patient may advance directly to an anti-TNF antibody (without ever using an immunomodulator). Alternatively, for patients who are already on an immunomodulator, this is discontinued as soon as the anti-TNF agent is started. Monotherapy may be safer than combination therapy, as outlined above, and some data suggest that "optimized monotherapy" (where <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> interval and dose are adjusted based on drug levels rather than using the standard dose) may improve efficacy and reduce loss of response, thus avoiding the need for combination therapy [<a href="#rid122">122</a>].</p><p></p><p>Data from adult studies and other considerations regarding concomitant immunosuppressive agents are discussed in more detail in a separate topic review. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a>.)</p><p class="headingAnchor" id="H1228651009"><span class="h2">Second-line biologic agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates and rationale</strong> – Candidates for second-line biologic agents are individuals with nonresponse despite therapeutic anti-TNF antibody drug levels (ie, trough <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> levels ≥10 micrograms/mL):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary nonresponse – Up to one-third of patients treated with <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> do not respond [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Secondary loss of response – Among patients who had an initial response to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>, approximately 13 percent develop secondary loss of response each year [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent1">For these groups of patients, further treatment with <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> or <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> has relatively low success rates [<a href="#rid123">123</a>]. Therefore, treatment with <a class="drug drug_pediatric" data-topicid="126474" href="/d/drug information/126474.html" rel="external">ustekinumab</a> or <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> is used by some experts, based on good outcomes with clinical experience, indirect evidence from studies in adults, and observational studies in children, as outlined below. This evidence supports the medical necessity of these drugs in selected patients. (See <a class="local">'Medical necessity of off-label use of medications in pediatrics'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ustekinumab</strong> – <a class="drug drug_pediatric" data-topicid="126474" href="/d/drug information/126474.html" rel="external">Ustekinumab</a> is a monoclonal antibody that binds to the p40 subunit of interleukin (IL)-12 and IL-23. It has received FDA approval to be utilized in adults with CD but is used off-label in children. Limited data have been reported in children with plaque psoriasis, rheumatoid arthritis, and CD. Observational studies suggest that ustekinumab is efficacious in children with CD unresponsive to anti-TNF [<a href="#rid125">125-128</a>]. In adults, ustekinumab is given with an induction dose based on body weight (260 mg for &lt;55 kg, 390 mg for 55 to 85 kg, 520 mg for &gt;85 kg), followed by 90 mg given subcutaneously every two months.</p><p></p><p class="bulletIndent1">One retrospective case series described outcomes of <a class="drug drug_pediatric" data-topicid="126474" href="/d/drug information/126474.html" rel="external">ustekinumab</a> treatment of 52 pediatric patients with IBD (80 percent with CD), 81 percent of whom had failed other biologic agents [<a href="#rid127">127</a>]. After 52 weeks of therapy, 75 percent of patients were still on ustekinumab therapy, the majority of whom required dose escalation. Steroid-free remission was achieved in 50 percent of patients who had failed other biologic agents and 90 percent of those who had not been exposed to other biologic agents. A second multicenter retrospective study of 44 patients demonstrated similar results, with 77 percent of patients remaining on ustekinumab for one year and 39 percent of those achieving clinical remission. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Anti-interleukin antibody therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vedolizumab</strong> – <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> is a humanized anti-alpha-4-beta-7 integrin monoclonal antibody that inhibits T-lymphocyte migration into the gastrointestinal tract. It is administered intravenously at weeks 0, 2, and 6 for induction and then maintenance with every four to eight weeks depending on disease severity, with more severe disease requiring four-week dosing [<a href="#rid129">129,130</a>]. Pediatric weight-based dosing is 6 mg/kg, to a maximum dose of 300 mg [<a href="#rid129">129,130</a>].</p><p></p><p class="bulletIndent1">All pediatric studies are retrospective cohort studies, which show lower response rates compared with other biologic agents [<a href="#rid129">129-131</a>]. Therefore, it is generally used as a second- or third-line therapy for patients with primary nonresponse or secondary loss of response to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> (or biosimilar) or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>. In patients who had failed one or more TNF-alpha antagonists, week 14 and 22 remission rates range between 30 to 45 percent [<a href="#rid129">129,130</a>]. Steroid-free remission at week 22 ranges from 20 to 30 percent [<a href="#rid129">129-131</a>]. <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> has been shown to have efficacy in adults with CD, either as first-line therapy [<a href="#rid132">132</a>] or after loss of response to an anti-TNF agent [<a href="#rid133">133-135</a>]. Its use in pediatric patients is often limited to those with loss of response to an anti-TNF, in part due to insurance denials of this and other off-label uses of drugs. (See <a class="local">'Medical necessity of off-label use of medications in pediatrics'</a> below.)</p><p></p><p class="bulletIndent1">Notably, <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> has a delayed onset of action compared with other biologic agents, particularly in individuals with severe refractory disease with loss of response to TNF-alpha antagonists. Little significant clinical response is appreciated until weeks 14 to 22 [<a href="#rid131">131,133,136</a>]. This delayed onset suggests that vedolizumab may not target preexisting inflammation but instead may inhibit propagation of further inflammation by inhibiting T-lymphocyte trafficking to the gut. Furthermore, treating the transmural inflammation seen in CD may require longer therapy than with ulcerative colitis, which may be why response rates in ulcerative colitis are faster and higher [<a href="#rid136">136</a>]. Additionally, TNF-alpha antagonists downregulate MAdCAM-1 expression; thus, patients with anti-TNF administered before vedolizumab may require more time to respond to this drug [<a href="#rid133">133,136</a>].</p><p></p><p class="bulletIndent1">A significant benefit of <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> use is its milder side effect profile in comparison with other biologics. The actions and immunosuppressive effects of vedolizumab are limited to the gastrointestinal tract, in contrast with many other therapies for CD that are systemically immunosuppressive, including TNF-alpha antagonists, immunomodulators, and <a class="drug drug_pediatric" data-topicid="126474" href="/d/drug information/126474.html" rel="external">ustekinumab</a>. Furthermore, vedolizumab does not increase the risk of malignancy, which has been reported with these other CD therapies. The main potential side effect of vedolizumab is infusion reactions.</p><p></p><p class="headingAnchor" id="H1592578570"><span class="h2">Medical necessity of off-label use of medications in pediatrics</span><span class="headingEndMark"> — </span>Use of second-line biologic agents and/or escalation of doses beyond those approved by the FDA may be appropriate and medically necessary for selected children with CD. The decision should be based on individual patient characteristics and clinical judgement by an expert clinician. In the United States, some insurance companies and payors have been denying coverage for these medically necessary therapies, stating that the use is "experimental," which usually is not the case. According to a position statement by the American Academy of Pediatrics: "The purpose of off-label use is to benefit the individual patient. Practitioners use their professional judgment to determine these uses. As such, the term 'off-label' does not imply an improper, illegal, contraindicated, or investigational use. Therapeutic decision-making must always rely on the best available evidence and the importance of the benefit for the individual patient" [<a href="#rid137">137</a>].</p><p>Substantial evidence supports a role for dose escalation, therapeutic drug monitoring, and utilization of drugs that are approved for adults in the management of pediatric CD. In many cases of refractory IBD, off-label use is medically necessary and is in the patient's best interest. The evidence supporting these off-label uses is outlined under each of the drugs. If the medically necessary treatment is denied by a payer, the clinician may advocate for the patient by providing medical details on the patient case and including relevant medical literature supporting the utilization of an off-label treatment [<a href="#rid138">138,139</a>]. (See <a class="local">'Second-line biologic agents'</a> above and <a class="local">'Dose and administration'</a> above.)</p><p class="headingAnchor" id="H1232351528"><span class="h2">Immunomodulators</span><span class="headingEndMark"> — </span>Thiopurines and MTX are immunomodulatory drugs that are sometimes used for maintenance therapy in CD. When used as monotherapy, they are generally considered second-line options because biologic agents (eg, <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>) have somewhat better risk/benefit profile for most patients. Immunomodulators can also be used in combination with a biologic agent, either to reduce antibody formation or for refractory cases (see <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> above). Specific considerations are outlined below.</p><p class="headingAnchor" id="H155976456"><span class="h3">Mercaptopurine and azathioprine</span><span class="headingEndMark"> — </span>The thiopurine drugs <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> (AZA) and mercaptopurine (also known as <a class="drug drug_pediatric" data-topicid="12582" href="/d/drug information/12582.html" rel="external">6-mercaptopurine</a> [6-MP]) are one of several options for maintenance treatment of moderate or severe CD  (<a class="graphic graphic_algorithm graphicRef64031" href="/d/graphic/64031.html" rel="external">algorithm 1</a>). They can be used in combination with a biologic agent (eg, <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>) but are sometimes used as monotherapy. Their use has declined since the early 2000s because they have limited efficacy as monotherapy and because of concerns about the small risk of lymphoma associated with thiopurines. These concerns have prompted a trend toward other maintenance regimens, including a biologic agent alone or in combination with MTX or, possibly, MTX monotherapy. Nevertheless, thiopurines warrant consideration in some cases because of their long history of use and efficacy in CD. (See <a class="local">'Safety and monitoring'</a> below.)</p><p>In the liver, 6-MP and AZA are converted to 6-thioguanine (6-TG) nucleotides, which inhibit lymphocyte proliferation by impairing DNA synthesis. 6-MP or AZA may require two to four months of treatment to achieve their maximal effect. Thus, they are not useful as induction agents.</p><p class="headingAnchor" id="H1088803394"><span class="h4">Dose</span><span class="headingEndMark"> — </span>Because AZA is metabolized into 6-MP, the drugs are equally effective and differ only in their dosing. In children, standard doses for AZA are 1.5 to 2.5 mg/kg/day orally (maximum dose 200 mg/day). 6-MP is generally given at doses between 1 to 1.5 mg/kg/day orally (maximum 150 mg/day). Some patients may benefit from doses above this range (eg, 6-MP 2 mg/kg/day), if appropriately monitored for toxicity. As an example, one observational report suggests that younger children (&lt;6 years) may require doses at the higher end of this range or above (median AZA equivalent 3.1 mg/kg/day) to achieve clinical remission [<a href="#rid140">140</a>]. All children treated with these drugs should be monitored closely for signs of toxicity, as discussed below.</p><p>Because of genetic variation in metabolism of thiopurines, the optimal dose of these drugs varies. To determine a safe starting dose, we suggest evaluating patients for the thiopurine methyltransferase genotype (TPMT genotype) or phenotype (TPMT activity) prior to beginning treatment with 6-MP or AZA. TPMT is an enzyme that is essential in the metabolism of thiopurines. Approximately 90 percent of patients are homozygous for the allele TPMT 1 (ie, TPMT 1/1 genotype) and have normal or rapid metabolism of thiopurines. In contrast, 10 percent of patients have reduced TPMT activity (eg, TPMT 1/3a genotype) and metabolize thiopurines more slowly. These patients typically respond to much lower doses of the medication (eg, 0.5 mg/kg/day of 6-MP). Approximately 1 in 300 patients has absent TPMT activity (eg, TPMT 3a/3a genotype) and does not metabolize the medication. These patients are at high risk for pancytopenia and should not be treated with thiopurines. A second genetic polymorphism, in the <em>NUDT15 </em>gene (nudix hydrolase 15), has also been shown to correlate with neutropenia, particularly in Asian patients. Since not all genetic panels incorporate assessing for this genotype, monitoring of leukocyte counts remains important in IBD patients on thiopurines [<a href="#rid141">141</a>].</p><p class="headingAnchor" id="H3973374056"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Clinical remission rates in patients treated with 6-MP and AZA monotherapy vary in clinical trials but are probably around 30 percent, as suggested by a large registry study in the United States [<a href="#rid142">142</a>]. Similar remission rates were reported for the SONIC trial in adults [<a href="#rid47">47</a>]. A considerably higher remission rate (90 percent at 18 months) was suggested by a smaller earlier trial in children with new-onset CD [<a href="#rid143">143</a>]. Overall, it is generally accepted that the remission rate for patients treated with 6-MP or AZA is lower than the remission rate for patients treated with anti-tumor necrosis factor (anti-TNF) antibodies, such as <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H2522800611"><span class="h4">Safety and monitoring</span><span class="headingEndMark"> — </span>6-MP and AZA are generally well tolerated by children. Toxicities of these drugs include some that are dose dependent (bone marrow suppression and hepatotoxicity) and others that are dose independent (eg, nausea, pancreatitis, infection, malignancy) [<a href="#rid144">144</a>]. Because of these issues, patients treated with 6-MP or AZA require frequent monitoring.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring and bone marrow suppression</strong> – Routine monitoring during thiopurine treatment can help to optimize dosing and reduce the risk of bone marrow suppression and hepatotoxicity, which are dose-dependent side effects. Mild leukopenia occurs in approximately 10 percent of children during treatment with thiopurines and responds to dose reduction [<a href="#rid144">144</a>]. Severe bone marrow suppression is a rare but potentially life-threatening side effect, usually associated with absent TPMT activity.</p><p></p><p class="bulletIndent1">In our practice, we monitor patients by performing a complete blood count (CBC) and aminotransferase levels (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) before treatment and again at 2, 4, 8, and 12 weeks after initiating therapy. If the results are normal, we monitor every three months thereafter and two to three weeks after a change in dose. If significant leukopenia (white blood cell [WBC] count &lt;3000) is detected, thiopurine treatment should be interrupted and/or the dose reduced.</p><p></p><p class="bulletIndent1">If TPMT testing is not available, then a thiopurine may be started at a low dose, followed by close monitoring of CBC. Our protocol is to check the CBC biweekly for two months, then monthly for four more months; if the WBC count falls to between 2000 and 4000/mm<sup>3</sup>, we reduce the thiopurine dose by 50 percent [<a href="#rid145">145</a>]. If the WBC falls below 2000/mm<sup>3</sup>, we stop the thiopurine and check the CBC every 10 days until the WBC returns to normal, at which time a lower dose of thiopurine can be tried, if necessary.</p><p></p><p class="bulletIndent1">Monitoring of blood levels of 6-TG (the active metabolite) and 6-methylmercaptopurine (6-MMP; the hepatotoxic metabolite) also can be helpful in assessing drug metabolism and compliance and in optimizing drug dosing [<a href="#rid146">146,147</a>]. However, there is a wide range of response (and toxicity) across a range of erythrocyte 6-TG levels. Therefore, genotyping and metabolite testing does not substitute for conventional laboratory monitoring for toxicity, with periodic measurements of a CBC and aminotransferases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The target range for 6-TG is between 235 to 450 pmol/8 x 10(8) erythrocytes [<a href="#rid146">146</a>]. Patients with 6-TG above this range are at risk for bone marrow suppression, so the CBC should be monitored and consideration should be given to decreasing the dose.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some patients who are rapid metabolizers will have high levels of 6-MMP (above 5000 pmol/8 x 10(8) erythrocytes). High 6-MMP levels are associated with an increased risk of elevated aminotransferases. For these patients, the addition of <a class="drug drug_pediatric" data-topicid="13339" href="/d/drug information/13339.html" rel="external">allopurinol</a> in combination with a reduced 6-MP dose (decreased by at least 50 percent) can shunt metabolism away from the 6-MMP metabolite and toward increased 6-TG production by inhibiting the enzyme xanthine oxidase [<a href="#rid148">148</a>]. Thus, combination therapy of a lower dose of 6-MP with allopurinol can improve therapeutic effects and decrease hepatotoxicity. This approach has been shown to be effective in pediatrics, improving remission rates, decreasing corticosteroid use, and allowing patients to maintain on an oral therapy rather than escalating to an anti-TNF medication [<a href="#rid149">149</a>]. However, because combination treatment with allopurinol can raise the 6-TG level and lead to potentially life-threatening bone marrow suppression, it is important to monitor patients closely with CBC at 2, 4, 8, and 12 weeks until it is clear that there are no adverse effects on a stable dose of allopurinol and 6-MP. We do not recommend using an allopurinol and thiopurine combination unless monitoring of 6-TG and 6-MMP levels is readily available, due to the risk of high levels and myelosuppression. In our practice, we rarely utilize combination allopurinol and <a class="drug drug_pediatric" data-topicid="12582" href="/d/drug information/12582.html" rel="external">mercaptopurine</a> due to the availability of other options to treat IBD.</p><p></p><p class="bulletIndent1">The use of 6-MP and AZA in adults and details about metabolite monitoring are discussed in separate topic reviews. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease"</a> and  <a class="medical medical_review" href="/d/html/4058.html" rel="external">"Thiopurines: Pretreatment testing and approach to therapeutic drug monitoring for adults with inflammatory bowel disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – Like other immunomodulators or biologic agents, treatment with 6-MP or AZA increases a patient's susceptibility to bacterial, fungal, and viral infections. We suggest pretreatment screening for tuberculosis and special considerations for vaccines, as outlined in a separate topic review. Acute Epstein-Barr virus (EBV) infection warrants temporary discontinuation of the thiopurine because mononucleosis in a patient on thiopurines may be associated with malignancy, as described below. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Infection risk'</a> and  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Immunizations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malignancy</strong> – 6-MP and AZA are also associated with a small increased risk of developing lymphoma, some of which are associated with infection with EBV [<a href="#rid3">3,144,150-154</a>]. The risk of lymphoproliferative disease is substantially increased in patients who develop primary EBV disease while on immunosuppressive therapy, particularly thiopurines [<a href="#rid56">56</a>]. As a result, some experts have suggested screening for EBV seropositivity prior to thiopurine treatment [<a href="#rid155">155</a>]. This is particularly relevant for adolescents since a majority will experience primary EBV infection in late adolescence or early adulthood [<a href="#rid156">156</a>]. However, there is no consensus about whether thiopurines should be avoided in patients who have not had primary EBV infection. The absolute risk of lymphoproliferative disease associated with thiopurines is probably very low (&lt;1 per 1000 patient-years in one adult cohort [<a href="#rid157">157</a>]), but the risks in children and the relative risks for lymphoproliferative disease associated with thiopurines versus other immunosuppressive therapies have not been established. Some reassurance comes from a study in 192 pediatric patients who were seronegative for EBV when they began thiopurine treatment [<a href="#rid158">158</a>]. Seven patients (4 percent) experienced seroconversion to EBV, and most were symptomatic, but none developed EBV-associated lymphoproliferative disease.</p><p></p><p class="bulletIndent1">In patients who are receiving thiopurines who develop active EBV infection (as documented by clinical symptoms, elevated EBV immunoglobulin M [IgM], and positive polymerase chain reaction [PCR]), immunosuppressive therapy should be stopped until the infection resolves, if possible. It is unclear if other immune-suppressive treatments (MTX, <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a>) should also be held in active EBV infection. The risk of lymphoma related to treatment with 6-MP/AZA in patients with CD is discussed separately. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Malignancy'</a>.)</p><p></p><p class="bulletIndent1">A small number of cases of HSTCL have been reported in adolescents and young adults during treatment with a combination of medicines known to suppress the immune system, including anti-TNF antibodies, AZA, and/or 6-MP; a few cases were in patients receiving AZA or 6-MP alone [<a href="#rid83">83,85,159-163</a>]. Most reported cases are in young males. Because HSTCL is otherwise extremely rare (approximately 100 cases have been reported in the literature), it is unlikely that these cases are due to chance alone. The thiopurine is thought to be the primary risk factor for HSTCL, both because some cases occurred on thiopurine monotherapy and because thiopurines are known to raise the risk of lymphoma; anti-TNF monotherapy is less likely to be associated with lymphoma, although data are limited [<a href="#rid83">83</a>]. The small risk of lymphoma must be weighed against the benefits of combination treatment, including better disease control and decreased rate of antibody formation, as discussed below [<a href="#rid164">164</a>]. (See  <a class="medical medical_review" href="/d/html/4056.html" rel="external">"Overview of azathioprine and mercaptopurine use in inflammatory bowel disease", section on 'Malignancy'</a> and <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> above.)</p><p></p><p class="bulletIndent1">Patients with IBD have an increased risk for melanoma and nonmelanoma skin cancer. Limited data suggest that nonmelanoma skin cancer may be most closely related to the use of thiopurines, while melanoma skin cancer may be more associated with anti-TNF therapy [<a href="#rid83">83</a>]. (See  <a class="medical medical_review" href="/d/html/96979.html" rel="external">"Important health maintenance issues for children and adolescents with inflammatory bowel disease", section on 'Surveillance for cancer'</a>.)</p><p></p><p class="bulletIndent1">The true long-term risks of lymphoma and other malignancies in children receiving immunosuppressive therapies are unknown. Most available data suggest a mildly increased risk of malignancy in patients receiving these medications, but the actual risk remains low (eg, approximately 7 cases per 10,000 patient years) [<a href="#rid74">74,111,165,166</a>]. In addition, there is some uncertainty about which medications or combinations are associated with these malignancies. We and most other experts believe that in children with moderate to severe CD that is refractory to conventional treatment, the established benefit of these therapies generally exceeds the risk of a slight increase in chance of developing lymphoma. However, these potential benefits and risks should be explained in detail to the patient and family before selecting a therapy or combination therapy. (See <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pancreatitis</strong> – Acute pancreatitis is an uncommon side effect of 6-MP and AZA, reported in approximately 5 percent of adults and 1 percent of pediatric patients using these drugs for IBD, representing a sixfold increase in risk compared with a relevant control group [<a href="#rid144">144,167,168</a>]. The risk appears to be limited to the first 90 days of treatment, is not dose dependent, and typically resolves when the drug is withdrawn [<a href="#rid167">167</a>].</p><p></p><p class="headingAnchor" id="H3831460458"><span class="h4">Early use of thiopurines</span><span class="headingEndMark"> — </span>Treatment with thiopurines early in the course of CD has been shown to reduce the likelihood of relapse. This was shown in a trial in children with newly diagnosed CD, in which children treated with 6-MP had reduced steroid use and fewer relapses compared with those treated with placebo [<a href="#rid1">1,143</a>]. However, this strategy is being used less frequently due to concerns about complications of thiopurines. Such complications include leukopenia, opportunistic infections, and an increased risk of lymphoma, as discussed above. Instead, use of thiopurines is typically limited to patients with a demonstrated need for maintenance therapy, such as those with moderate or severe CD or those who relapse when steroids are withdrawn. Even for this group of patients, there is a trend to select alternate immunosuppressive agents, including anti-TNF antibodies or MTX. (See <a class="local">'Anti-tumor necrosis factor antibody medications'</a> above.)</p><p class="headingAnchor" id="H2107225464"><span class="h3">Methotrexate</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> – Intramuscular or subcutaneous MTX given once a week is a second-line therapy for maintenance of remission and is primarily used in combination with a biologic agent. Indeed, some clinicians prefer to use MTX rather than thiopurines for combination therapy because of concerns that combination treatment with thiopurines and anti-TNF antibodies may increase risk for lymphoma. A randomized controlled trial found that the combination of MTX and <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> did not improve remission rates compared with infliximab alone, but the combination was associated with a reduced prevalence of antibodies to infliximab, raising the possibility that combination therapy may reduce loss of response to infliximab [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monotherapy</strong> – MTX monotherapy is moderately effective in maintaining remission in children. A meta-analysis of 14 observational studies including 886 children reported a clinical remission rate of 58 percent at three to six months (95% CI 48-67 percent) and 37 percent at 12 months (95% CI 30-46 percent) [<a href="#rid169">169</a>]. In a retrospective review of 65 pediatric patients who initiated MTX maintenance monotherapy, 21 percent had mucosal healing, 49 percent of patients were in clinical remission, and 45 percent had changed to alternate therapies after one year [<a href="#rid170">170</a>]. Similar findings were seen in a meta-analysis of studies in adults, which concluded that patients receiving MTX had lower rates of disease relapse compared with those receiving placebo (65 percent versus 39 percent) [<a href="#rid171">171</a>]. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Methotrexate'</a>.)</p><p></p><p class="bulletIndent1">MTX monotherapy probably has very limited benefit for inducing (as distinct from maintaining) remission, based primarily on studies in adults [<a href="#rid172">172,173</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and administration</strong> – MTX typically is given in children at a dose of 15 mg/m<sup>2</sup> per week (up to a maximum of 25 mg per week, which is the dose used for adults) [<a href="#rid2">2,174,175</a>]. On occasion, slightly higher doses are used [<a href="#rid176">176</a>]. We suggest giving the drug subcutaneously for three to six months to ensure absorption. Patients who successfully enter remission may be switched to oral MTX, although no randomized trials are available to establish the efficacy of oral MTX [<a href="#rid175">175,177-179</a>]. The best available information comes from a multicenter retrospective study of subcutaneous versus oral MTX that demonstrated comparable one-year steroid-free clinical remission rates (overall steroid-free remission rate 34 percent) [<a href="#rid179">179</a>]. This study utilized propensity score modeling to adjust for the variables such as disease severity and MTX drug dose that might bias treatment selection (eg, less sick patients were treated with oral MTX, while sicker patients were treated with subcutaneous MTX, or higher doses given via the subcutaneous route). Interestingly, in this study, patients who were initially given subcutaneous MTX and converted to oral MTX had the highest remission rate (45 percent steroid-free remission), but this may reflect a center-specific effect because most such patients were treated at one hospital.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Use of MTX is limited by its side effects, which include nausea, myelosuppression, oral ulcers, infection, pulmonary abnormalities, and hepatitis. Therefore, we recommend monitoring of the CBC and aminotransferases, as with thiopurine therapy. To minimize the nausea, MTX is given at bedtime; if nausea persists, it may be treated with medications such as <a class="drug drug_pediatric" data-topicid="12659" href="/d/drug information/12659.html" rel="external">ondansetron</a>. We routinely give <a class="drug drug_pediatric" data-topicid="13322" href="/d/drug information/13322.html" rel="external">folic acid</a> 1 mg daily because folic acid supplementation may reduce the likelihood of gastrointestinal symptoms, liver enzyme abnormalities, and oral ulcers [<a href="#rid180">180</a>].</p><p></p><p class="bulletIndent1">MTX is strictly contraindicated in pregnancy and should be discontinued in both females and males at least three months prior to conception. (See  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Prevention of side effects with folate'</a>.)</p><p></p><p class="headingAnchor" id="H1673527272"><span class="h2">Aminosalicylates</span><span class="headingEndMark"> — </span>5-aminosalicylate (5-ASA) medications may be used as maintenance therapy in children with mild CD  (<a class="graphic graphic_algorithm graphicRef64031" href="/d/graphic/64031.html" rel="external">algorithm 1</a>). They are generally well tolerated, but their efficacy in CD is unclear. There are no good randomized controlled trials of aminosalicylate treatment for mild CD in children, and it is unclear if these medications have any efficacy in moderate to severe CD.</p><p>The family of 5-ASA medications includes <a class="drug drug_pediatric" data-topicid="12817" href="/d/drug information/12817.html" rel="external">sulfasalazine</a>, <a class="drug drug_pediatric" data-topicid="12584" href="/d/drug information/12584.html" rel="external">mesalamine</a>, <a class="drug drug_general" data-topicid="9717" href="/d/drug information/9717.html" rel="external">olsalazine</a>, <a class="drug drug_pediatric" data-topicid="13082" href="/d/drug information/13082.html" rel="external">balsalazide</a>, and mesalamine-Multi-Matrix (MMX), each of which has a 5-ASA moiety. The 5-ASA is readily absorbed throughout the small intestine; therefore, the parent compound generally must be modified for site-specific use in CD. Most of the studies of mesalamine preparations in CD are more than two decades old, did not utilize mucosal healing as an endpoint, and showed only mild efficacy over placebo. (See  <a class="medical medical_review" href="/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p>All of these medications are designed to deliver the 5-ASA moiety to the colon, where the 5-ASA inhibits synthesis of proinflammatory prostaglandins and leukotrienes. The timed-release formulation (Pentasa) and pH-sensitive release formulation (Asacol) have enteric coatings that help to deliver medication to the proximal and distal small intestine, respectively, making these 5-ASA preparations potentially useful in the treatment of diffuse small bowel CD and Crohn ileocolitis [<a href="#rid181">181</a>]. (See  <a class="medical medical_review" href="/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p>In adults, at least two 5-ASA agents (Pentasa and Asacol) were slightly superior to placebo (remission rate 40 percent for ASA versus 30 percent for placebo) in inducing remission in active CD. High doses of Pentasa (4 g/day, 16 pills a day) or Asacol (at least 3.2 g/day, 8 pills a day) must be used to achieve these modest effects [<a href="#rid182">182</a>]. Similarly, <a class="drug drug_pediatric" data-topicid="12584" href="/d/drug information/12584.html" rel="external">mesalamine</a> has a slight benefit (risk difference for relapse 5 to 10 percent over placebo) in preventing relapses of CD in adults [<a href="#rid183">183</a>]. No pediatric studies have evaluated the efficacy of these medications in children with CD. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p>Most aminosalicylates other than <a class="drug drug_pediatric" data-topicid="12817" href="/d/drug information/12817.html" rel="external">sulfasalazine</a> can be started in their full doses. Sulfasalazine should be started at a low dose (eg, 25 mg/kg/day) and increased gradually, according to the patient's tolerance, up to 50 to 75 mg/kg/day (maximum dose of 4 to 6 g/day). Because sulfasalazine competitively inhibits folate absorption, patients should be treated simultaneously with folate (1 mg/day) [<a href="#rid184">184,185</a>]. Sulfasalazine and <a class="drug drug_general" data-topicid="9717" href="/d/drug information/9717.html" rel="external">olsalazine</a> can be compounded into a suspension for young children to drink. It is recommended that other aminosalicylates be swallowed whole; however, capsules of Pentasa containing granules or <a class="drug drug_pediatric" data-topicid="13082" href="/d/drug information/13082.html" rel="external">balsalazide</a> containing powder may be opened and administered by sprinkling the contents on soft food.</p><p>Aminosalicylates generally are well tolerated. Approximately 20 percent of patients will have dose-limiting side effects with <a class="drug drug_pediatric" data-topicid="12817" href="/d/drug information/12817.html" rel="external">sulfasalazine</a>, with the most common adverse reactions being headaches, photosensitivity, and skin rash. Studies in adults have highlighted concerns about an association with renal disease, including interstitial nephritis [<a href="#rid186">186</a>]. Other side effects seen with sulfasalazine include a hypersensitivity reaction (manifested by fever, skin rash, and adenopathy), hepatitis, pancreatitis, leukopenia, and decreased sperm count. Other aminosalicylates also may have side effects (eg, rash, pancreatitis, proteinuria, interstitial nephritis, pneumonitis, pericarditis), but these are infrequent. Nevertheless, monitoring of patients on aminosalicylates should include CBCs (suggested frequency at least twice a year), creatinine, and urinalysis (suggested frequency at least annually to screen for interstitial nephritis). (See  <a class="medical medical_review" href="/d/html/4065.html" rel="external">"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H3526420875"><span class="h2">Antibiotics</span><span class="headingEndMark"> — </span>Antibiotics are important components of treatment for patients with abdominal abscess and are used in conjunction with percutaneous drainage [<a href="#rid187">187</a>]. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Abdominal abscess'</a>.)</p><p>Antibiotics also have a limited role in the treatment of mild active CD, both for patients with perianal disease [<a href="#rid3">3</a>] and also for those with colonic disease [<a href="#rid2">2</a>]. Agents such as <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> or <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> have efficacy comparable to aminosalicylates in the treatment of mild active CD [<a href="#rid188">188</a>]. Combination therapy with <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> and metronidazole was explored in a randomized trial in children with mild or moderate CD, in which 66 percent of patients treated with combination therapy achieved remission at eight weeks compared with 39 percent for those on metronidazole monotherapy [<a href="#rid189">189</a>]. This response to antibiotics in children appears to be better than that for adults. Limitations of this study include the absence of a maintenance arm and lack of data on endoscopic remission. Nevertheless, this remains a potential option for patients in whom the clinician wishes to avoid immunosuppression or who do not respond to other therapies.</p><p>Limited evidence suggests that antibiotics may have a role as "salvage" therapy in patients with refractory colonic disease. This was shown in a case series of 63 patients with ileocolonic or colonic disease (43 percent CD, 36 percent ulcerative colitis, 21 percent IBD-unclassified) who were failing anti-TNF treatment and were refractory to or dependent on glucocorticoids, in whom a combination antibiotic regimen achieved a clinical response in more than 60 percent and remission in 40 percent [<a href="#rid190">190</a>]. Among the subset of patients with acute severe colitis, 27 percent (7 of 26 patients) achieved remission. These findings suggest that combination antibiotics may be useful to induce remission during transition to a maintenance medication with delayed onset of efficacy, such as <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a>.</p><p>The primary side effects of <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> are metallic taste, nausea, a <a class="drug drug_general" data-topicid="9379" href="/d/drug information/9379.html" rel="external">disulfiram</a> reaction if taken with alcohol, peripheral neuropathy with long-term use, and a possible risk for fetal effects if taken during early pregnancy (see  <a class="medical medical_review" href="/d/html/464.html" rel="external">"Metronidazole: An overview", section on 'Toxicity'</a>). <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">Ciprofloxacin</a> is generally reserved for more resistant organisms because resistance can develop during therapy [<a href="#rid187">187</a>]. Ciprofloxacin is generally well tolerated; reported side effects include stomach upset, allergic reactions, increased risk for <em>Clostridioides</em> <em>difficile</em> infection, and tendonitis or tendon rupture. Treatment with <a class="drug drug_pediatric" data-topicid="94528" href="/d/drug information/94528.html" rel="external">rifaximin</a> has been associated with modest improvement in preliminary studies in adults [<a href="#rid191">191</a>]. Adverse effects of <a class="drug drug_pediatric" data-topicid="12937" href="/d/drug information/12937.html" rel="external">azithromycin</a> include gastrointestinal side effects, hepatotoxicity, and QT prolongation. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Perianal disease'</a> and  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults", section on 'Antibiotics'</a> and  <a class="medical medical_review" href="/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Adverse reactions'</a>.)</p><p class="headingAnchor" id="H3536826638"><span class="h2">Other medications</span><span class="headingEndMark"> — </span>A variety of therapies have been used for patients not responding to any of the above agents [<a href="#rid3">3,50</a>]. Most of the available information about these therapies comes from studies in adults, and treatment decisions in pediatric patients are made on a case-by-case basis. Given the potential toxicities of these potent immunosuppressive agents and/or limited evidence of benefit, we suggest they be reserved either for patients enrolled in a clinical trial or for patients who have not responded to immunomodulators or to the biologic agents described above. (See <a class="local">'First-line biologic agents'</a> above and <a class="local">'Second-line biologic agents'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Certolizumab</strong> – <a class="drug drug_general" data-topicid="8644" href="/d/drug information/8644.html" rel="external">Certolizumab pegol</a> consists of the antigen-binding (Fab) fragment of a humanized anti-TNF monoclonal antibody, which is covalently attached to a polyethylene glycol moiety to increase the half-life. It is a second- or third-line anti-TNF agent for CD in adults, typically used for those who responded to <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a>, then lost response due to development of antibodies, or became intolerant to these drugs (eg, infusion reactions or lupus-like reactions). One relatively rare instance where certolizumab is particularly helpful is as rescue therapy in patients who develop infliximab-induced lupus (symmetric large joint arthralgias, high-titer antinuclear antibodies [ANA] and anti-double-stranded DNA antibodies). Discontinuing infliximab and switching to certolizumab or adalimumab has been shown to manage CD symptoms without leading to recurrence of the infliximab-induced lupus [<a href="#rid192">192</a>]. Certolizumab is administered subcutaneously. Induction dosing for adults is 400 mg at weeks 0, 2, and 4, followed by 400 mg every four weeks for maintenance of remission. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults", section on 'Choice of anti-TNF agent'</a>.)</p><p></p><p class="bulletIndent1">There are no pediatric studies of certolizumab to date. When studied in adults with moderate to severe luminal CD, remission (defined by a Crohn disease activity index [CDAI] &lt;150) by week 6 was 22 percent for certolizumab and 17 percent for placebo, and response (defined as a decrease in CDAI of 100 points) by week 6 was 35 percent to certolizumab and 27 percent to placebo [<a href="#rid193">193</a>]. Response rates are somewhat lower for patients previously exposed to anti-TNF therapies [<a href="#rid193">193,194</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Golimumab</strong> – <a class="drug drug_pediatric" data-topicid="129934" href="/d/drug information/129934.html" rel="external">Golimumab</a> is a recombinant human monoclonal antibody that neutralizes TNF-alpha activity. It is currently approved for adults with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis and has been approved for adults with ulcerative colitis but not CD. (See  <a class="medical medical_review" href="/d/html/4054.html" rel="external">"Overview of dosing and monitoring of biologic agents and small molecules for treating ulcerative colitis in adults", section on 'Golimumab'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thalidomide</strong> – <a class="drug drug_pediatric" data-topicid="13090" href="/d/drug information/13090.html" rel="external">Thalidomide</a>, an inhibitor of both TNF and angiogenesis, has been used off-label to treat refractory IBD for more than a decade. Published case series, our own clinical experience, and a randomized trial suggest that it is an effective agent [<a href="#rid195">195-197</a>]. Toxicities include neuropathy, leukopenia, and profound congenital anomalies in the offspring of women who took thalidomide during pregnancy. For this reason, thalidomide is tightly monitored and regulated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tacrolimus</strong> – <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">Tacrolimus</a> was effective in randomized trials in adults with refractory CD and observational studies in children but generally does not yield long-term remission, and the renal toxicity of this agent limits its long-term use [<a href="#rid198">198-200</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclosporine</strong> – <a class="drug drug_pediatric" data-topicid="13193" href="/d/drug information/13193.html" rel="external">Cyclosporine</a> has been effective in the acute treatment of fistulizing disease in adults, but the effect is highly variable, and it is probably not helpful in maintaining remission [<a href="#rid201">201</a>].</p><p></p><p class="headingAnchor" id="H1324627105"><span class="h2">Complementary and alternative therapies</span><span class="headingEndMark"> — </span>Patients often seek advice from practitioners of alternative medicine. In surveys of children with CD from six different IBD centers in the United States, 40 to 50 percent were using therapies not prescribed by their clinician [<a href="#rid202">202-204</a>]. The clinician should inquire about the use of herbs and dietary supplements since some of these complementary therapies may have gastrointestinal side effects [<a href="#rid202">202</a>]. The National Institutes of Health's <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F%2FvRJTX6pAh9HqPuMIdRDLCvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=120380" target="_blank">National Center for Complementary and Integrative Health</a> provides reliable information on complementary and alternative medicine practices. (See  <a class="medical medical_review" href="/d/html/2851.html" rel="external">"Complementary and integrative health in pediatrics"</a>.)</p><p class="headingAnchor" id="H1455674892"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113229.html" rel="external">"Society guideline links: Inflammatory bowel disease in children"</a>.)</p><p class="headingAnchor" id="H4246123016"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86454.html" rel="external">"Patient education: Crohn disease in children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H302578482"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – For Crohn disease (CD) affecting the ileum and/or colon, a variety of medications are available  (<a class="graphic graphic_table graphicRef65046" href="/d/graphic/65046.html" rel="external">table 1</a>). The choice of medication typically depends on disease location, severity, and response.</p><p></p><p class="bulletIndent1">These therapies can be grouped as induction therapies, which have relatively rapid onset of action, and maintenance therapies, which are appropriate for long-term use. Some of these therapies are appropriate for both induction and maintenance. An approach to selecting among these medications is summarized in the algorithms  (<a class="graphic graphic_algorithm graphicRef64031" href="/d/graphic/64031.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef75566" href="/d/graphic/75566.html" rel="external">algorithm 2</a>) and discussed in more detail in a separate topic review. (See  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Selection of medical treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – The main options are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoids</strong> – Systemic glucocorticoids are appropriate for induction in moderate to severe CD [<a href="#rid1">1</a>]. In the United States, glucocorticoids are a common initial treatment for the acute therapy. (See <a class="local">'Glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Exclusive or partial enteral nutrition</strong> – Exclusive enteral nutrition (EEN) is an appropriate approach for induction in patients with moderate to severe CD, especially for those with extensive small bowel involvement or growth failure. This approach is common in Canada, the United Kingdom, and Europe and less widely used in the United States. Partial enteral nutrition combined with a specific exclusion diet (CD exclusion diet) is an emerging strategy that may be more easily accepted by patients. (See <a class="local">'Exclusive or partial enteral nutrition'</a> above and  <a class="medical medical_review" href="/d/html/5866.html" rel="external">"Overview of the management of Crohn disease in children and adolescents", section on 'Nutritional therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infliximab</strong><strong> or </strong><strong>adalimumab</strong> – <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">Infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> can be used for induction or maintenance therapy. They are sometimes used for initial medical treatment of high-risk patients with severe disease or for those with moderate disease, due to patient preference and other patient-specific considerations. (See <a class="local">'Anti-tumor necrosis factor antibody medications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aminosalicylates</strong> – Aminosalicylates may be appropriate for induction and maintenance in mild ileocolonic CD, but data about their efficacy for treating this phenotype are limited. (See <a class="local">'Aminosalicylates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – The main options are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infliximab</strong><strong> or </strong><strong>adalimumab</strong> – The main biologic agents used for CD in children are <a class="drug drug_pediatric" data-topicid="13381" href="/d/drug information/13381.html" rel="external">infliximab</a> or <a class="drug drug_pediatric" data-topicid="13077" href="/d/drug information/13077.html" rel="external">adalimumab</a> (or their biosimilars), which are anti-tumor necrosis factor (anti-TNF) antibodies and can be used for both induction and maintenance. (See <a class="local">'First-line biologic agents'</a> above.)</p><p></p><p class="bulletIndent2">The relative risks and benefits of monotherapy with an anti-TNF antibody versus combination therapy with an immunomodulator (eg, 6-MP) remain unclear. In adults, combination therapy with an immunomodulator and biologic is more effective than use of either agent individually. A plain-language summary to guide discussions about treatment decisions is outlined in the table  (<a class="graphic graphic_table graphicRef107130" href="/d/graphic/107130.html" rel="external">table 6</a>). (See <a class="local">'Anti-TNF monotherapy versus combination therapy with an immunomodulator'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunomodulators</strong> – Immunomodulators used for CD are thiopurines (<a class="drug drug_pediatric" data-topicid="12582" href="/d/drug information/12582.html" rel="external">6-mercaptopurine</a> [6-MP] or <a class="drug drug_pediatric" data-topicid="12923" href="/d/drug information/12923.html" rel="external">azathioprine</a> [AZA]) and <a class="drug drug_pediatric" data-topicid="12595" href="/d/drug information/12595.html" rel="external">methotrexate</a> (MTX). These are appropriate only for maintenance because of delayed onset of action. (See <a class="local">'Mercaptopurine and azathioprine'</a> above and <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aminosalicylates</strong> – These have low efficacy and low toxicity, are used primarily for mild CD, and are appropriate for induction and maintenance. The choice of agent depends on disease location. (See <a class="local">'Aminosalicylates'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotics</strong> – Antibiotics are important components of treatment for patients with abdominal abscess and are used in conjunction with percutaneous drainage. Oral antibiotics such as <a class="drug drug_pediatric" data-topicid="13157" href="/d/drug information/13157.html" rel="external">ciprofloxacin</a> and <a class="drug drug_pediatric" data-topicid="12606" href="/d/drug information/12606.html" rel="external">metronidazole</a> also have a limited role in the treatment of mild active CD, especially for patients with perianal disease but also for those with colonic disease. (See <a class="local">'Antibiotics'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other medications</strong> – <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">Vedolizumab</a> and <a class="drug drug_pediatric" data-topicid="126474" href="/d/drug information/126474.html" rel="external">ustekinumab</a> are newer biologics with different mechanisms of action. Because of limited pediatric data, these drugs are used for nonresponders to immunomodulators and anti-TNF antibodies. A variety of other therapies, including certolizumab, <a class="drug drug_pediatric" data-topicid="129934" href="/d/drug information/129934.html" rel="external">golimumab</a>, <a class="drug drug_pediatric" data-topicid="13090" href="/d/drug information/13090.html" rel="external">thalidomide</a>, and <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a>, have been used for patients not responding to any of the above agents. Of note, use of second-line biologic agents and/or escalation of doses beyond those approved by the US Food and Drug Administration (FDA) may be appropriate and medically necessary for selected children with CD. (See <a class="local">'Second-line biologic agents'</a> above and <a class="local">'Other medications'</a> above and <a class="local">'Medical necessity of off-label use of medications in pediatrics'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kappelman MD, Bousvaros A, Hyams J, et al. Intercenter variation in initial management of children with Crohn's disease. Inflamm Bowel Dis 2007; 13:890.</a></li><li><a class="nounderline abstract_t">Sandhu BK, Fell JM, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. J Pediatr Gastroenterol Nutr 2010; 50 Suppl 1:S1.</a></li><li><a class="nounderline abstract_t">van Rheenen PF, Aloi M, Assa A, et al. The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update. J Crohns Colitis 2020.</a></li><li><a class="nounderline abstract_t">Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003; :CD000301.</a></li><li><a class="nounderline abstract_t">Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121:255.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143:1218.</a></li><li><a class="nounderline abstract_t">Escher JC, European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004; 16:47.</a></li><li><a class="nounderline abstract_t">Levine A, Kori M, Dinari G, et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009; 15:1055.</a></li><li><a class="nounderline abstract_t">Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002; 140:75.</a></li><li><a class="nounderline abstract_t">Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2003; 36:248.</a></li><li><a class="nounderline abstract_t">Kundhal P, Zachos M, Holmes JL, Griffiths AM. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001; 33:75.</a></li><li><a class="nounderline abstract_t">Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005; 21:363.</a></li><li><a class="nounderline abstract_t">Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14:281.</a></li><li><a class="nounderline abstract_t">Day AS, Whitten KE, Sidler M, Lemberg DA. Systematic review: nutritional therapy in paediatric Crohn's disease. Aliment Pharmacol Ther 2008; 27:293.</a></li><li><a class="nounderline abstract_t">Tjellström B, Högberg L, Stenhammar L, et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease. Scand J Gastroenterol 2012; 47:1454.</a></li><li><a class="nounderline abstract_t">Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988; 94:603.</a></li><li><a class="nounderline abstract_t">Levine A, Wine E, Assa A, et al. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology 2019; 157:440.</a></li><li><a class="nounderline abstract_t">Gordon M. 5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence. World J Gastrointest Pharmacol Ther 2017; 8:99.</a></li><li class="breakAll">US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Available at: www.accessdata.fda.gov/scripts/cder/drugsatfda (Accessed on August 30, 2006).</li><li><a class="nounderline abstract_t">Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20:1708.</a></li><li><a class="nounderline abstract_t">Zitomersky NL, Atkinson BJ, Fournier K, et al. Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD. Inflamm Bowel Dis 2015; 21:307.</a></li><li><a class="nounderline abstract_t">deBruyn JC, Jacobson K, El-Matary W, et al. Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience. J Pediatr Gastroenterol Nutr 2018; 66:268.</a></li><li><a class="nounderline abstract_t">Hofmekler T, Bertha M, McCracken C, et al. Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2017; 64:580.</a></li><li><a class="nounderline abstract_t">Frymoyer A, Piester TL, Park KT. Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease. J Pediatr Gastroenterol Nutr 2016; 62:723.</a></li><li><a class="nounderline abstract_t">Hoekman DR, Brandse JF, de Meij TG, et al. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand J Gastroenterol 2015; 50:1110.</a></li><li><a class="nounderline abstract_t">Winter DA, Joosse ME, de Wildt SN, et al. Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations. J Pediatr Gastroenterol Nutr 2020; 70:763.</a></li><li><a class="nounderline abstract_t">Jongsma MME, Winter DA, Huynh HQ, et al. Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 2020; 179:1935.</a></li><li><a class="nounderline abstract_t">Assa A, Dorfman L, Shouval DS, et al. Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series. J Pediatr Gastroenterol Nutr 2020; 71:516.</a></li><li><a class="nounderline abstract_t">Uzel G, Orange JS, Poliak N, et al. Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis. Clin Infect Dis 2010; 51:1429.</a></li><li><a class="nounderline abstract_t">Kelsen JR, Sullivan KE, Rabizadeh S, et al. North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2020; 70:389.</a></li><li><a class="nounderline abstract_t">Kerur B, Fiedler K, Stahl M, et al. Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America. J Pediatr Gastroenterol Nutr 2022; 75:64.</a></li><li><a class="nounderline abstract_t">Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19:2568.</a></li><li><a class="nounderline abstract_t">Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009; 15:816.</a></li><li><a class="nounderline abstract_t">Frymoyer A, Hoekman DR, Piester TL, et al. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. J Pediatr Gastroenterol Nutr 2017; 65:639.</a></li><li><a class="nounderline abstract_t">Papamichael K, Cheifetz AS. Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy. Am J Gastroenterol 2017; 112:673.</a></li><li><a class="nounderline abstract_t">Govani SM, Waljee AK. Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled. Am J Gastroenterol 2017; 112:670.</a></li><li><a class="nounderline abstract_t">Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease. Gut 2015; 64:1539.</a></li><li><a class="nounderline abstract_t">Ungar B, Levy I, Yavne Y, et al. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016; 14:550.</a></li><li><a class="nounderline abstract_t">Syversen SW, Jørgensen KK, Goll GL, et al. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. JAMA 2021; 326:2375.</a></li><li><a class="nounderline abstract_t">Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol 2019; 4:341.</a></li><li><a class="nounderline abstract_t">Courbette O, Aupiais C, Viala J, et al. Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. J Pediatr Gastroenterol Nutr 2020; 70:310.</a></li><li><a class="nounderline abstract_t">Chi LY, Zitomersky NL, Liu E, et al. The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2018; 24:1344.</a></li><li><a class="nounderline abstract_t">Cohen RZ, Schoen BT, Kugathasan S, Sauer CG. Management of Anti-drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019; 69:551.</a></li><li><a class="nounderline abstract_t">Minar P, Saeed SA, Afreen M, et al. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016; 62:715.</a></li><li><a class="nounderline abstract_t">Shapiro JM, Subedi S, Machan JT, et al. Durability of Infliximab Is Associated With Disease Extent in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016; 62:867.</a></li><li><a class="nounderline abstract_t">Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108:962.</a></li><li><a class="nounderline abstract_t">Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.</a></li><li><a class="nounderline abstract_t">Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337:1029.</a></li><li><a class="nounderline abstract_t">Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398.</a></li><li><a class="nounderline abstract_t">Faubion WA Jr, Bousvaros A. Medical therapy for refractory pediatric Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:1199.</a></li><li><a class="nounderline abstract_t">Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137:192.</a></li><li><a class="nounderline abstract_t">Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95:3189.</a></li><li><a class="nounderline abstract_t">Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003; 98:833.</a></li><li><a class="nounderline abstract_t">de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr 2004; 39:46.</a></li><li><a class="nounderline abstract_t">Lamireau T, Cézard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004; 10:745.</a></li><li><a class="nounderline abstract_t">Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007; 132:863.</a></li><li><a class="nounderline abstract_t">Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease. Inflamm Bowel Dis 2014; 20:1177.</a></li><li><a class="nounderline abstract_t">Cameron FL, Wilson ML, Basheer N, et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience. Arch Dis Child 2015; 100:399.</a></li><li><a class="nounderline abstract_t">Oussalah A, Chevaux JB, Fay R, et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am J Gastroenterol 2010; 105:1142.</a></li><li><a class="nounderline abstract_t">Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63:1258.</a></li><li><a class="nounderline abstract_t">Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:1133.</a></li><li><a class="nounderline abstract_t">Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin 2011; 27:651.</a></li><li><a class="nounderline abstract_t">Nuti F, Viola F, Civitelli F, et al. Biological therapy in a pediatric Crohn disease population at a referral center. J Pediatr Gastroenterol Nutr 2014; 58:582.</a></li><li><a class="nounderline abstract_t">Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis 2013; 7:369.</a></li><li><a class="nounderline abstract_t">de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis 2008; 14:353.</a></li><li><a class="nounderline abstract_t">Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr 2009; 49:183.</a></li><li><a class="nounderline abstract_t">Kelsen JR, Grossman AB, Pauly-Hubbard H, et al. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr 2014; 59:758.</a></li><li><a class="nounderline abstract_t">Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000; 95:3469.</a></li><li><a class="nounderline abstract_t">Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis 2005; 11:442.</a></li><li><a class="nounderline abstract_t">Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr 2007; 96:128.</a></li><li><a class="nounderline abstract_t">Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124:917.</a></li><li><a class="nounderline abstract_t">Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601.</a></li><li><a class="nounderline abstract_t">Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003; 17:75.</a></li><li><a class="nounderline abstract_t">Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol 2014; 12:1443.</a></li><li><a class="nounderline abstract_t">Ardura MI, Toussi SS, Siegel JD, et al. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. J Pediatr Gastroenterol Nutr 2016; 63:130.</a></li><li class="breakAll">American Acedemy of Pediatrics. Infectious complications with the use of biologic response modifiers in infants and children. Available at: http://pediatrics.aappublications.org/content/pediatrics/early/2016/07/14/peds.2016-1209.full.pdf (Accessed on July 19, 2016).</li><li><a class="nounderline abstract_t">Danziger-Isakov L. Infections in Children on Biologics. Infect Dis Clin North Am 2018; 32:225.</a></li><li><a class="nounderline abstract_t">Noguera-Julian A, Calzada-Hernández J, Brinkmann F, et al. Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑ Agents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study. Clin Infect Dis 2020; 71:2561.</a></li><li><a class="nounderline abstract_t">Chuang MH, Singh J, Ashouri N, et al. Listeria meningitis after infliximab treatment of ulcerative colitis. J Pediatr Gastroenterol Nutr 2010; 50:337.</a></li><li><a class="nounderline abstract_t">Jordan N, Waghmare A, Abi-Ghanem AS, et al. Systemic Mycobacterium avium complex infection during antitumor necrosis factor-α therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2012; 54:294.</a></li><li><a class="nounderline abstract_t">Dotson JL, Crandall W, Mousa H, et al. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis 2011; 17:56.</a></li><li class="breakAll">US Food and Drug Administration. MedWatch. Available at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm (Accessed on August 05, 2009).</li><li><a class="nounderline abstract_t">Day AS, Gulati AS, Patel N, et al. The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66:361.</a></li><li><a class="nounderline abstract_t">Llanos-Chea A, Shapiro JM, Winter RW, et al. Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series. Dig Dis Sci 2022; 67:252.</a></li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy. Available at: http://www.fda.gov/drugs/drugsafety/ucm278267.htm (Accessed on September 26, 2014).</li><li><a class="nounderline abstract_t">Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013; 57:1318.</a></li><li><a class="nounderline abstract_t">Mostamand S, Schroeder S, Schenkein J, Miloh T. Infliximab-Associated Immunomediated Hepatitis in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2016; 63:94.</a></li><li><a class="nounderline abstract_t">Bertrand V, Massy N, Pigneur B, et al. Neurological Adverse Effects Associated With Anti-tumor Necrosis Factor Alpha Antibodies in Pediatric Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr 2020; 70:841.</a></li><li><a class="nounderline abstract_t">Baumer FM, Ouahed J, Verhave M, Rivkin MJ. Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease. Pediatr Neurol 2016; 57:91.</a></li><li><a class="nounderline abstract_t">Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 52:230.</a></li><li><a class="nounderline abstract_t">Eickstaedt JB, Killpack L, Tung J, et al. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatr Dermatol 2017; 34:253.</a></li><li><a class="nounderline abstract_t">Courbette O, Aupiais C, Viala J, et al. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019; 69:189.</a></li><li><a class="nounderline abstract_t">Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr 2013; 56:512.</a></li><li><a class="nounderline abstract_t">Pollard B, Utterson EC, Samson CM, Coughlin CC. Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study. Pediatr Dermatol 2022; 39:563.</a></li><li><a class="nounderline abstract_t">Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:210.</a></li><li><a class="nounderline abstract_t">Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014; 12:265.</a></li><li><a class="nounderline abstract_t">O'Connell DM, Nachreiner J, Shu X, et al. Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2022; 74:605.</a></li><li><a class="nounderline abstract_t">de Ridder L, Assa A, Bronsky J, et al. Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 2019; 68:144.</a></li><li><a class="nounderline abstract_t">Socal MP, Ezebilo I, Bai G, Anderson GF. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab. Am J Health Syst Pharm 2021; 78:216.</a></li><li><a class="nounderline abstract_t">Dipasquale V, Cicala G, Spina E, Romano C. Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Front Pharmacol 2022; 13:846151.</a></li><li><a class="nounderline abstract_t">Wyneski MJ, Green A, Kay M, et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 47:19.</a></li><li><a class="nounderline abstract_t">Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1683.</a></li><li><a class="nounderline abstract_t">Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci 2010; 55:747.</a></li><li><a class="nounderline abstract_t">Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol 2009; 104:2566.</a></li><li><a class="nounderline abstract_t">Dubinsky MC, Rosh J, Faubion WA Jr, et al. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease. Inflamm Bowel Dis 2016; 22:886.</a></li><li><a class="nounderline abstract_t">Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol 2009; 104:3042.</a></li><li><a class="nounderline abstract_t">Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. Gastroenterology 2012; 143:365.</a></li><li><a class="nounderline abstract_t">Assa A, Matar M, Turner D, et al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring. Gastroenterology 2019; 157:985.</a></li><li><a class="nounderline abstract_t">Matar M, Shamir R, Lev-Zion R, et al. The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial. J Pediatr Gastroenterol Nutr 2020; 71:237.</a></li><li><a class="nounderline abstract_t">Matar M, Shamir R, Turner D, et al. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial. Inflamm Bowel Dis 2020; 26:1627.</a></li><li><a class="nounderline abstract_t">Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012; 18:838.</a></li><li><a class="nounderline abstract_t">Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32:119.</a></li><li><a class="nounderline abstract_t">Parakkal D, Sifuentes H, Semer R, Ehrenpreis ED. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk. Eur J Gastroenterol Hepatol 2011; 23:1150.</a></li><li><a class="nounderline abstract_t">Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013; 108:99.</a></li><li><a class="nounderline abstract_t">Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol 2012; 107:1409.</a></li><li><a class="nounderline abstract_t">Kansen HM, van Rheenen PF, Houwen RHJ, et al. Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators. J Pediatr Gastroenterol Nutr 2017; 65:425.</a></li><li><a class="nounderline abstract_t">Cheng J, Hamilton Z, Smyth M, et al. Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2017; 23:1762.</a></li><li><a class="nounderline abstract_t">Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134:1861.</a></li><li><a class="nounderline abstract_t">Grossi V, Lerer T, Griffiths A, et al. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease. Clin Gastroenterol Hepatol 2015; 13:1748.</a></li><li><a class="nounderline abstract_t">El-Matary W, Carroll MW, Debruyn JC, et al. Discontinuation of Immunosuppressive Medications in Children With Inflammatory Bowel Disease on Combination Therapy. J Pediatr Gastroenterol Nutr 2020; 71:740.</a></li><li><a class="nounderline abstract_t">Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology 2014; 146:681.</a></li><li><a class="nounderline abstract_t">Lega S, Phan BL, Rosenthal CJ, et al. Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD. Inflamm Bowel Dis 2019; 25:134.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Marín AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 2015; 41:613.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104:760.</a></li><li><a class="nounderline abstract_t">Bishop C, Simon H, Suskind D, et al. Ustekinumab in Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 2016; 63:348.</a></li><li><a class="nounderline abstract_t">Rinawi F, Rosenbach Y, Assa A, Shamir R. Ustekinumab for Resistant Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2016; 62:e34.</a></li><li><a class="nounderline abstract_t">Dayan JR, Dolinger M, Benkov K, et al. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center. J Pediatr Gastroenterol Nutr 2019; 69:61.</a></li><li><a class="nounderline abstract_t">Kim FS, Patel PV, Stekol E, et al. Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease. J Pediatr Gastroenterol Nutr 2021; 73:610.</a></li><li><a class="nounderline abstract_t">Singh N, Rabizadeh S, Jossen J, et al. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22:2121.</a></li><li><a class="nounderline abstract_t">Schneider AM, Weghuber D, Hetzer B, et al. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol 2018; 18:140.</a></li><li><a class="nounderline abstract_t">Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22:2425.</a></li><li><a class="nounderline abstract_t">Feagan BG, Lasch K, Lissoos T, et al. Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019; 17:130.</a></li><li><a class="nounderline abstract_t">Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147:618.</a></li><li><a class="nounderline abstract_t">Hanauer SB. Reviewing the Use of Vedolizumab for the Treatment of Patients With Crohn’s Disease. Gastroenterol Hepatol 2022; 18.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711.</a></li><li><a class="nounderline abstract_t">Shelton E, Allegretti JR, Stevens B, et al. Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis 2015; 21:2879.</a></li><li><a class="nounderline abstract_t">Frattarelli DA, Galinkin JL, Green TP, et al. Off-label use of drugs in children. Pediatrics 2014; 133:563.</a></li><li><a class="nounderline abstract_t">Bhat S, Zahorian T, Robert R, Farraye FA. Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process. Inflamm Bowel Dis 2019; 25:1621.</a></li><li><a class="nounderline abstract_t">Jaff JC, Arnold J, Bousvaros A. Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers. Inflamm Bowel Dis 2006; 12:814.</a></li><li><a class="nounderline abstract_t">Grossman AB, Noble AJ, Mamula P, Baldassano RN. Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger. Inflamm Bowel Dis 2008; 14:750.</a></li><li><a class="nounderline abstract_t">Sutiman N, Chen S, Ling KL, et al. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. Pharmacogenomics 2018; 19:31.</a></li><li><a class="nounderline abstract_t">Boyle BM, Kappelman MD, Colletti RB, et al. Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. World J Gastroenterol 2014; 20:9185.</a></li><li><a class="nounderline abstract_t">Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895.</a></li><li><a class="nounderline abstract_t">Miele E, Benninga MA, Broekaert I, et al. Safety of Thiopurine Use in Paediatric Gastrointestinal Disease. J Pediatr Gastroenterol Nutr 2020; 71:156.</a></li><li><a class="nounderline abstract_t">Rosen R, Integlia MJ, Bousvaros A. Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. J Pediatr Gastroenterol Nutr 2002; 35:695.</a></li><li><a class="nounderline abstract_t">Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705.</a></li><li><a class="nounderline abstract_t">Benkov K, Lu Y, Patel A, et al. Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD. J Pediatr Gastroenterol Nutr 2013; 56:333.</a></li><li><a class="nounderline abstract_t">Chocair P, Duley J, Simmonds HA, et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993; 342:83.</a></li><li><a class="nounderline abstract_t">Serpico MR, Maltz R, Crandall W, et al. Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr 2018; 67:341.</a></li><li><a class="nounderline abstract_t">Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.</a></li><li><a class="nounderline abstract_t">Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115:813.</a></li><li><a class="nounderline abstract_t">Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122:72.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med 2015; 372:1441.</a></li><li><a class="nounderline abstract_t">Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. Clin Gastroenterol Hepatol 2015; 13:847.</a></li><li><a class="nounderline abstract_t">Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8:443.</a></li><li><a class="nounderline abstract_t">Gordon J, Ramaswami A, Beuttler M, et al. EBV Status and Thiopurine Use in Pediatric IBD. J Pediatr Gastroenterol Nutr 2016; 62:711.</a></li><li><a class="nounderline abstract_t">Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617.</a></li><li><a class="nounderline abstract_t">Harris RE, Hegde V, Curtis L, et al. Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population. J Pediatr Gastroenterol Nutr 2021; 73:358.</a></li><li><a class="nounderline abstract_t">Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265.</a></li><li><a class="nounderline abstract_t">Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40:220.</a></li><li><a class="nounderline abstract_t">Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48:386.</a></li><li><a class="nounderline abstract_t">Ochenrider MG, Patterson DJ, Aboulafia DM. Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. Clin Lymphoma Myeloma Leuk 2010; 10:144.</a></li><li><a class="nounderline abstract_t">de Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. Inflamm Bowel Dis 2014; 20:291.</a></li><li><a class="nounderline abstract_t">Bern EM, Bousvaros A. Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum. Expert Rev Clin Immunol 2013; 9:117.</a></li><li><a class="nounderline abstract_t">Peneau A, Savoye G, Turck D, et al. Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. Am J Gastroenterol 2013; 108:1647.</a></li><li><a class="nounderline abstract_t">Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. Gastroenterology 2017; 152:1901.</a></li><li><a class="nounderline abstract_t">Wintzell V, Svanström H, Olén O, et al. Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study. Lancet Child Adolesc Health 2019; 3:158.</a></li><li><a class="nounderline abstract_t">Teich N, Mohl W, Bokemeyer B, et al. Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity. J Crohns Colitis 2016; 10:61.</a></li><li><a class="nounderline abstract_t">Colman RJ, Lawton RC, Dubinsky MC, Rubin DT. Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2018; 24:2135.</a></li><li><a class="nounderline abstract_t">Baldwin K, Goldfarb A, Brimacombe M, et al. Methotrexate for Primary Maintenance Therapy in Mild-to-Moderate Crohn Disease in Children. J Pediatr Gastroenterol Nutr 2022; 75:320.</a></li><li><a class="nounderline abstract_t">Patel V, Wang Y, MacDonald JK, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2014; :CD006884.</a></li><li><a class="nounderline abstract_t">Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020; 20:100271.</a></li><li><a class="nounderline abstract_t">McDonald JW, Wang Y, Tsoulis DJ, et al. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2014; :CD003459.</a></li><li><a class="nounderline abstract_t">Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998; 132:830.</a></li><li><a class="nounderline abstract_t">Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol 2007; 102:2804.</a></li><li><a class="nounderline abstract_t">Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis 2006; 12:1053.</a></li><li><a class="nounderline abstract_t">Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr 2009; 48:526.</a></li><li><a class="nounderline abstract_t">Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2005; 40:445.</a></li><li><a class="nounderline abstract_t">Turner D, Doveh E, Cohen A, et al. Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study. Gut 2015; 64:1898.</a></li><li><a class="nounderline abstract_t">Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2013; :CD000951.</a></li><li><a class="nounderline abstract_t">Leichtner AM. Aminosalicylates for the treatment of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1995; 21:245.</a></li><li><a class="nounderline abstract_t">Gisbert JP, Gomollón F, Maté J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002; 47:471.</a></li><li><a class="nounderline abstract_t">Cammà C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113:1465.</a></li><li><a class="nounderline abstract_t">Santucci NR, Alkhouri RH, Baker RD, Baker SS. Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 59:455.</a></li><li><a class="nounderline abstract_t">Heyman MB, Garnett EA, Shaikh N, et al. Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease. Am J Clin Nutr 2009; 89:545.</a></li><li><a class="nounderline abstract_t">Muller AF, Stevens PE, McIntyre AS, et al. Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom. Aliment Pharmacol Ther 2005; 21:1217.</a></li><li><a class="nounderline abstract_t">Pfefferkorn MD, Marshalleck FE, Saeed SA, et al. NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula. J Pediatr Gastroenterol Nutr 2013; 57:394.</a></li><li><a class="nounderline abstract_t">Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91:328.</a></li><li><a class="nounderline abstract_t">Levine A, Kori M, Kierkus J, et al. Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. Gut 2019; 68:239.</a></li><li><a class="nounderline abstract_t">Breton J, Kastl A, Hoffmann N, et al. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019; 25:1586.</a></li><li><a class="nounderline abstract_t">Prantera C, Lochs H, Grimaldi M, et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142:473.</a></li><li><a class="nounderline abstract_t">Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011; 17:99.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol 2011; 9:670.</a></li><li><a class="nounderline abstract_t">Bousvaros A, Mueller B. Thalidomide in gastrointestinal disorders. Drugs 2001; 61:777.</a></li><li><a class="nounderline abstract_t">Lazzerini M, Martelossi S, Magazzù G, et al. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013; 310:2164.</a></li><li><a class="nounderline abstract_t">Lazzerini M, Villanacci V, Pellegrin MC, et al. Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide. Clin Gastroenterol Hepatol 2017; 15:1382.</a></li><li><a class="nounderline abstract_t">Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137:794.</a></li><li><a class="nounderline abstract_t">Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125:380.</a></li><li><a class="nounderline abstract_t">Truffinet O, Martinez-Vinson C, Guerriero E, et al. Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series. J Pediatr Gastroenterol Nutr 2017; 64:721.</a></li><li><a class="nounderline abstract_t">Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321:845.</a></li><li><a class="nounderline abstract_t">Heuschkel R, Afzal N, Wuerth A, et al. Complementary medicine use in children and young adults with inflammatory bowel disease. Am J Gastroenterol 2002; 97:382.</a></li><li><a class="nounderline abstract_t">Wong AP, Clark AL, Garnett EA, et al. Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey. J Pediatr Gastroenterol Nutr 2009; 48:55.</a></li><li><a class="nounderline abstract_t">Phatak UP, Alper A, Pashankar DS. Complementary and Alternative Medicine Use in Children With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019; 68:157.</a></li></ol></div><div id="topicVersionRevision">Topic 120380 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17286275" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Intercenter variation in initial management of children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20081543" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Guidelines for the management of inflammatory bowel disease in children in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33026087" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Corticosteroids for maintenance of remission in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487534" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22892337" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Once-daily budesonide MMX®extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095852" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229988" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11815767" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548062" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A comparison of budesonide and prednisone for the treatment of active pediatric Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479412" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15709986" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10735920" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18045244" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Systematic review: nutritional therapy in paediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23016828" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of exclusive enteral nutrition on gut microflora function in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3123302" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic intermittent elemental diet improves growth failure in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31170412" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533918" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28533918" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : 5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25153505" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25569737" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibodies to infliximab are associated with lower infliximab levels and increased likelihood of surgery in pediatric IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657923" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Long-term Outcomes of Infliximab Use for Pediatric Crohn Disease: A Canadian Multicenter Clinical Practice Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079601" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26890885" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25865965" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443029" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease: A Systematic Review and Revised Dosing Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32813123" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Infliximab in young paediatric IBD patients: it is all about the dosing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639454" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Therapeutic Drug Monitoring-guided High-dose Infliximab for Infantile-onset Inflammatory Bowel Disease: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21058909" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Complications of tumor necrosis factor-αblockade in chronic granulomatous disease-related colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32079889" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early-onset Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35622080" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24013361" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19107783" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Long-term outcome of maintenance infliximab therapy in children with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28471911" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28220781" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Therapeutic Drug Monitoring in IBD: The New Standard-of-Care for Anti-TNF Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28323274" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Therapeutic Drug Monitoring in IBD: Prospective Promise Unfulfilled.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25336114" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538204" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Optimizing Anti-TNF-αTherapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34932077" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30824404" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31651668" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29718278" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The Impact of Combination Therapy on Infliximab Levels and Antibodies in Children and Young Adults With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31335833" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Management of Anti-drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26551317" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26583483" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Durability of Infliximab Is Associated With Disease Extent in Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419382" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antibody response to infliximab and its impact on pharmacokinetics can be transient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20393175" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Infliximab, azathioprine, or combination therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9321530" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10228190" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Infliximab for the treatment of fistulas in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16872913" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Medical therapy for refractory pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10931411" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Use of infliximab in the treatment of Crohn's disease in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11095340" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738464" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15187780" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15626892" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324398" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24865777" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25678594" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Anti-TNF therapy for paediatric IBD: the Scottish national experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20389296" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24041539" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20145610" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21241207" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24343280" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Biological therapy in a pediatric Crohn disease population at a referral center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22483567" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18069674" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19561542" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25419596" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Infliximab therapy in pediatric patients 7 years of age and younger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11151879" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Infliximab in Crohn's disease: first anniversary clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15867583" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17187619" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12671888" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12584368" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12492735" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24462626" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27027903" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-αInhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27027903" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-αInhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29233577" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Infections in Children on Biologics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31796965" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tuberculosis Disease in Children and Adolescents on Therapy With Antitumor Necrosis Factor-ɑAgents: A Collaborative, Multicenter Paediatric Tuberculosis Network European Trials Group (ptbnet) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19841597" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Listeria meningitis after infliximab treatment of ulcerative colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21694635" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Systemic Mycobacterium avium complex infection during antitumor necrosis factor-αtherapy in pediatric Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20645322" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20645322" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29210919" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The Role of Combination Therapy in Pediatric Inflammatory Bowel Disease: A Clinical Report from the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595782" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595782" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23899685" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-αinhibitors: systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26835903" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Infliximab-Associated Immunomediated Hepatitis in Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32443044" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Neurological Adverse Effects Associated With Anti-tumor Necrosis Factor Alpha Antibodies in Pediatric Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26831951" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fatal Central Nervous System Disease Following First Infliximab Infusion in a Child With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21240020" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Infliximab-induced psoriasis in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28211161" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30921262" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23274341" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35342990" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Immunosuppressant-associated eruptions in pediatric inflammatory bowel disease: A case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23644389" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23602821" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35149648" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Rapid Infliximab Biosimilar Infusion in Children With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169454" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Use of Biosimilars in Pediatric Inflammatory Bowel Disease: An Updated Position Statement of the Pediatric IBD Porto Group of ESPGHAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33289035" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35370732" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18607264" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Safety and efficacy of adalimumab in pediatric patients with Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18618629" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Short-term response to adalimumab in childhood inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333754" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Adalimumab treatment in children with refractory Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19550415" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26950307" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19724267" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22562021" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31194979" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32324651" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31793630" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn's Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21887728" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20412066" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21941193" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Hepatosplenic T-cell lymphoma in patients receiving TNF-αinhibitor therapy: expanding the groups at risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032984" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890223" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945207" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28837517" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440315" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25911120" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32740529" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Discontinuation of Immunosuppressive Medications in Children With Inflammatory Bowel Disease on Combination Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24269926" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29868777" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25652884" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174781" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26854655" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Ustekinumab in Pediatric Crohn Disease Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25023579" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Ustekinumab for Resistant Pediatric Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31058718" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34415711" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Experience Using Ustekinumab in Pediatric Patients With Medically Refractory Crohn Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27542130" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30219028" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Vedolizumab use after failure of TNF-αantagonists in children and adolescents with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27598742" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29857145" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859203" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Reviewing the Use of Vedolizumab for the Treatment of Patients With Crohn’s Disease</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964933" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Vedolizumab as induction and maintenance therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26288002" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24567009" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Off-label use of drugs in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30753551" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Advocating for Patients With Inflammatory Bowel Disease: How to Navigate the Prior Authorization Process.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16917236" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Effective advocacy for patients with inflammatory bowel disease: communication with insurance companies, school administrators, employers, and other health care overseers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18266236" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29210335" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25083093" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040176" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32520827" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Safety of Thiopurine Use in Paediatric Gastrointestinal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454589" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10734022" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23287804" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8100914" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29601433" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22516861" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9753482" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11781282" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25853748" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Cancers complicating inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24879926" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24613021" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26655944" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : EBV Status and Thiopurine Use in Pediatric IBD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837455" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34091548" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Epstein-Barr Virus Status and Subsequent Thiopurine Exposure Within a Paediatric Inflammatory Bowel Disease Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255842" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699701" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19274799" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371449" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24374875" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390943" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Loss of response to biologics versus increased risk of lymphoma in children with inflammatory bowel disease: the clinician's conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23939626" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28193515" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30685366" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Association between use of azathioprine and risk of acute pancreatitis in children with inflammatory bowel disease: a Swedish-Danish nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26468141" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases--A Prospective Study on Incidence and Severity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29688409" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35758420" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Methotrexate for Primary Maintenance Therapy in Mild-to-Moderate Crohn Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25157445" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Methotrexate for maintenance of remission in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32300735" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099640" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Methotrexate for induction of remission in refractory Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602195" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Methotrexate in patients with Crohn's disease after 6-mercaptopurine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18042110" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075346" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19412004" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15795592" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : The bioavailability of oral methotrexate in children with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416066" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Efficacy of oral methotrexate in paediatric Crohn's disease: a multicentre propensity score study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728635" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8523207" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Aminosalicylates for the treatment of inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11911332" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9352848" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25000354" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Vitamin and zinc status pretreatment and posttreatment in patients with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19116333" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15882242" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23783018" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : NASPGHAN clinical report on the evaluation and treatment of pediatric patients with internal penetrating Crohn disease: intraabdominal abscess with and without fistula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607501" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29420227" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715364" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155172" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20629183" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17634458" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Certolizumab pegol for the treatment of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642014" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398909" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Thalidomide in gastrointestinal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24281461" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286192" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Endoscopic and Histologic Healing in Children With Inflammatory Bowel Diseases Treated With Thalidomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113835" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Oral tacrolimus treatment of severe colitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12891539" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27429426" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671739" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866277" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Complementary medicine use in children and young adults with inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19172124" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Use of complementary medicine in pediatric patients with inflammatory bowel disease: results from a multicenter survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30499887" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Complementary and Alternative Medicine Use in Children With Inflammatory Bowel Disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
